Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Lung Cancer

  Free Subscription


Articles published in Clin Lung Cancer

Retrieve available abstracts of 379 articles:
HTML format



Single Articles


    July 2022
  1. JOSHI I, Peravali M, Geng X, Rao S, et al
    Impact of Baseline Clinical Biomarkers on Treatment Outcomes in Patients With Advanced NSCLC Receiving First-line Pembrolizumab-Based Therapy.
    Clin Lung Cancer. 2022;23:438-445.
    PubMed     Abstract available


  2. BEHEL V, Chougule A, Noronha V, Patil VM, et al
    Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC.
    Clin Lung Cancer. 2022;23:410-418.
    PubMed     Abstract available


  3. SHINNO Y, Yoshida A, Masuda K, Matsumoto Y, et al
    Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor.
    Clin Lung Cancer. 2022;23:386-392.
    PubMed     Abstract available


  4. MAROONGROGE S, Weissferdt A, Buszek S, Rice DC, et al
    Management of Bronchial Adenoma/Ciliated Muconodular Papillary Tumor with Definitive Stereotactic Body Radiation Therapy (SBRT): A Case Report.
    Clin Lung Cancer. 2022;23:e335-e338.
    PubMed    


    June 2022
  5. VARLOTTO JM, Sun Z, Ky B, Upshaw J, et al
    A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181.
    Clin Lung Cancer. 2022 Jun 30. pii: S1525-7304(22)00149.
    PubMed     Abstract available


  6. OSTA BE, Carlisle J, Steuer C, Pakkala S, et al
    A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade.
    Clin Lung Cancer. 2022 Jun 22. pii: S1525-7304(22)00147.
    PubMed     Abstract available


  7. CARDONA AF, Ruiz-Patino A, Recondo G, Martin C, et al
    Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP).
    Clin Lung Cancer. 2022 Jun 6. pii: S1525-7304(22)00127.
    PubMed     Abstract available


  8. WALIANY S, Wakelee H, Ramchandran K, Das M, et al
    Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens.
    Clin Lung Cancer. 2022 Jun 3. pii: S1525-7304(22)00128.
    PubMed     Abstract available


  9. VIDETIC GMM, Reddy CA, Woody NM, Stephans KL, et al
    Local Control With Single-Fraction Lung Stereotactic Body Radiotherapy is not influenced by Non-Small Cell Lung Cancer Histologic Subtype.
    Clin Lung Cancer. 2022 Jun 3. pii: S1525-7304(22)00129.
    PubMed     Abstract available


  10. VEILLON R, Sakai H, Le X, Felip E, et al
    Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management.
    Clin Lung Cancer. 2022;23:320-332.
    PubMed     Abstract available


  11. COSTA BA, Maraveyas A, Wilkoff MH, Correia GSC, et al
    Primary Pulmonary NUT Carcinoma: Case Illustration and Updated Review of Literature.
    Clin Lung Cancer. 2022;23:e296-e300.
    PubMed    


  12. CAMIDGE DR, Moran T, Demedts I, Grosch H, et al
    A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib.
    Clin Lung Cancer. 2022;23:300-310.
    PubMed     Abstract available


  13. ANDRAOS TY, Halmos B, Cheng H, Huntzinger C, et al
    Disease Burden on PET Predicts Outcomes for Advanced NSCLC Patients Treated with First-Line Immunotherapy.
    Clin Lung Cancer. 2022;23:291-299.
    PubMed     Abstract available


  14. GUO Y, Wei L, Patel SH, Lopez G, et al
    Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy.
    Clin Lung Cancer. 2022;23:345-355.
    PubMed     Abstract available


  15. FEDERICO AD, Gelsomino F, De Biase D, Ardizzoni A, et al
    Should We Test Cancer Susceptibility Genes in Routinely Used Multigene Panels? A Case of Synchronous Lung Adenocarcinoma and Breast Cancer Associated With Germline CHEK2 Mutation.
    Clin Lung Cancer. 2022;23:e283-e284.
    PubMed    


    May 2022
  16. MORENO V, Roda D, Pikiel J, Trigo J, et al
    Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial.
    Clin Lung Cancer. 2022 May 23. pii: S1525-7304(22)00115.
    PubMed     Abstract available


  17. SIRGI Y, Krochmal R, Fleury CM, Holmes M, et al
    Pembrolizumab-Associated Cutaneous and Pulmonary Sarcoidosis in Non-Small Cell Lung Cancer Treatment.
    Clin Lung Cancer. 2022 May 20. pii: S1525-7304(22)00107.
    PubMed     Abstract available


  18. CUCCHIARA F, Petrini I, Passaro A, Attili I, et al
    Gene network Analysis Defines a Subgroup of Small Cell Lung Cancer patients With Short Survival.
    Clin Lung Cancer. 2022 May 20. pii: S1525-7304(22)00108.
    PubMed     Abstract available


  19. NAGATA S, Hamaji M, Ozasa H, Yamada Y, et al
    Salvage Surgery After Immune Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer: Potential Association Between Immune-Related Adverse Events and Longer Survival.
    Clin Lung Cancer. 2022 May 11. pii: S1525-7304(22)00098.
    PubMed    


  20. ZHU F, Wang H, Ashamalla H
    The Significance of Lymph Node Ratio and Total Lymph Nodes Examined in Determining the Indications of Adjuvant Radiation in pN2 Non-small Cell Lung Cancer.
    Clin Lung Cancer. 2022 May 11. pii: S1525-7304(22)00102.
    PubMed     Abstract available


  21. RIUDAVETS M, Lamberts V, Vasseur D, Auclin E, et al
    Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2022 May 11. pii: S1525-7304(22)00105.
    PubMed     Abstract available


  22. LIU SM, Yan HH, Wei XW, Lu C, et al
    Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non-Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG
    Clin Lung Cancer. 2022 May 11. pii: S1525-7304(22)00101.
    PubMed     Abstract available


  23. BIRONZO P, Primo L, Novello S, Righi L, et al
    Clinical-Molecular Prospective Cohort Study in Non-Small Cell Lung Cancer (PROMOLE study): A Comprehensive Approach to Identify New Predictive Markers of Pharmacological Response.
    Clin Lung Cancer. 2022 May 11. pii: S1525-7304(22)00100.
    PubMed     Abstract available


  24. FUKUSHIMA T, Oyamada Y, Ikemura S, Nukaga S, et al
    Real-world clinical practice for advanced non-small-cell lung cancer in the very elderly: A retrospective multicenter analysis.
    Clin Lung Cancer. 2022 May 11. pii: S1525-7304(22)00099.
    PubMed     Abstract available


  25. SCHNEIDER CS, Hatic H, Das D, Cardan RA, et al
    Patterns of Failure and Optimal Treatment Paradigm for Large, Inoperable, Node-Negative Non-small Cell Lung Cancer.
    Clin Lung Cancer. 2022 May 11. pii: S1525-7304(22)00103.
    PubMed     Abstract available


  26. SCHMID S, Minnella EM, Pilon Y, Rokah M, et al
    Neoadjuvant Prehabilitation Therapy for Locally Advanced Non-Small-Cell Lung Cancer: Optimizing Outcomes Throughout the Trajectory of Care.
    Clin Lung Cancer. 2022 May 11. pii: S1525-7304(22)00097.
    PubMed     Abstract available


  27. ZHOU Q, Wang M, Zhang H, Hong Q, et al
    Safety and Efficacy of Epitinib for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases: Open-Label Multicentre Dose-Expansion Phase Ib Study.
    Clin Lung Cancer. 2022 May 7. pii: S1525-7304(22)00037.
    PubMed     Abstract available


  28. MAYNE NR, Bajaj SS, Powell J, Elser HC, et al
    Extended Delay to Treatment for Stage III-IV Non-Small-Cell Lung Cancer and Survival: Balancing Risks During the COVID-19 Pandemic.
    Clin Lung Cancer. 2022 May 5. pii: S1525-7304(22)00069.
    PubMed     Abstract available


  29. SODJI QH, Harris JP, Quon A, Modlin LA, et al
    Detection of Recurrence After Thoracic Stereotactic Ablative Radiotherapy Using FDG-PET-CT.
    Clin Lung Cancer. 2022;23:282-289.
    PubMed     Abstract available


  30. WHITE MN, Piper-Vallillo AJ, Gardner RM, Cunanan K, et al
    Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.
    Clin Lung Cancer. 2022;23:e210-e221.
    PubMed     Abstract available


  31. FUJINO T, Suda K, Sakai K, Murakami I, et al
    Intra-tumor and Inter-tumor Heterogeneity in MET Exon 14 Skipping Mutations and Co-mutations in Pulmonary Pleomorphic Carcinomas.
    Clin Lung Cancer. 2022;23:e185-e195.
    PubMed     Abstract available


  32. BELLUOMINI L, Dionisi V, Palmerio S, Vincenzi S, et al
    Study Design and Rationale for Espera Trial: A Multicentre, Randomized, Phase II Clinical Trial Evaluating the Potential Efficacy of Adding SBRT to Pembrolizumab-Pemetrexed Maintenance in Responsive or Stable Advanced Non-Squamous NSCLC After Chemo-Im
    Clin Lung Cancer. 2022;23:e269-e272.
    PubMed     Abstract available


  33. REMON J, Girard N, Novello S, de Castro J, et al
    PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients.
    Clin Lung Cancer. 2022;23:e243-e246.
    PubMed     Abstract available


  34. YONEDA T, Sone T, Koba H, Shibata K, et al
    Long-Term Survival of Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor Monotherapy in Real-World Settings.
    Clin Lung Cancer. 2022 May 1. pii: S1525-7304(22)00055.
    PubMed     Abstract available


    April 2022
  35. SCHILD SE, Wang X, Bestvina CM, Williams T, et al
    Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer.
    Clin Lung Cancer. 2022 Apr 30. pii: S1525-7304(22)00065.
    PubMed     Abstract available


  36. RIMNER A, Lai WV, Califano R, Jabbour SK, et al
    Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer.
    Clin Lung Cancer. 2022 Apr 29. pii: S1525-7304(22)00058.
    PubMed     Abstract available


  37. ABDELGHANY K, Macaulay R, Tang Z, Tanvetyanon T, et al
    Pulmonary Ewing Sarcoma Mimicking Small Cell Lung Cancer.
    Clin Lung Cancer. 2022 Apr 29. pii: S1525-7304(22)00061.
    PubMed    


  38. MERKHOFER CM, Eastman B, Densmore I, Halasz LM, et al
    Systemic Treatment Patterns and Outcomes in Patients With EGFR Mutated Non-small Cell Lung Cancer and Leptomeningeal Disease.
    Clin Lung Cancer. 2022 Apr 29. pii: S1525-7304(22)00056.
    PubMed     Abstract available


  39. ROBINSON EM, Liu BY, Sigel K, Yin C, et al
    Impact of Comorbidities on Lung Cancer Screening Evaluation.
    Clin Lung Cancer. 2022 Apr 29. pii: S1525-7304(22)00054.
    PubMed     Abstract available


  40. MIKAMI N, Takeda A, Hashimoto A, Takeda T, et al
    CT Findings and Treatment Outcomes of Ground-Glass Opacity Predominant Lung Cancer After Stereotactic Body Radiotherapy.
    Clin Lung Cancer. 2022 Apr 29. pii: S1525-7304(22)00064.
    PubMed     Abstract available


  41. MAJEED H, Zhu H, Williams SA, Hamann HA, et al
    Prevalence And Impact of Medical Comorbidities in A Real-World Lung Cancer Screening Population.
    Clin Lung Cancer. 2022 Apr 29. pii: S1525-7304(22)00057.
    PubMed     Abstract available


  42. CAMIDGE DR, Mandair D, Morgan R, Amini A, et al
    Quantifying The Medical Impact of A Missed Diagnosis of Non-Small Cell Lung Cancer on Chest Imaging.
    Clin Lung Cancer. 2022 Apr 29. pii: S1525-7304(22)00059.
    PubMed     Abstract available


  43. JABBOUR SK, Cho BC, Bria E, Kato T, et al
    Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2022 Apr 29. pii: S1525-7304(22)00066.
    PubMed     Abstract available


  44. HANDA Y, Tsutani Y, Mimae T, Miyata Y, et al
    A Multicenter Study of Complex Segmentectomy Versus Wedge Resection in Clinical Stage 0-IA Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2022 Apr 27. pii: S1525-7304(21)00267.
    PubMed     Abstract available


  45. ZHANG C, Li F, Li J, Xu Y, et al
    Corrigendum to "Docetaxel downregulates PD-1 expression via STAT3 in Tlymphocytes" [Clinical Lung Cancer 19 (2018) e675-e683].
    Clin Lung Cancer. 2022 Apr 15. pii: S1525-7304(22)00040.
    PubMed    


    March 2022
  46. CIUNCI CA, Reibel JB, Evans TL, Mick R, et al
    Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed.
    Clin Lung Cancer. 2022 Mar 14. pii: S1525-7304(22)00034.
    PubMed     Abstract available


  47. HOLTZMAN L, Moskovitz M, Urban D, Nechushtan H, et al
    dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score >/=50.
    Clin Lung Cancer. 2022;23:122-134.
    PubMed     Abstract available


  48. PATHAK R, Salgia R
    Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma.
    Clin Lung Cancer. 2022;23:e137-e139.
    PubMed    


  49. SHAH MP, Aredo JV, Padda SK, Ramchandran KJ, et al
    EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.
    Clin Lung Cancer. 2022;23:e148-e153.
    PubMed     Abstract available


  50. ASEMOTA N, Saftic I, Tsitsias T, King J, et al
    Quality of Life in Octogenarians After Lung Resection Compared to Younger Patients.
    Clin Lung Cancer. 2022;23:e118-e130.
    PubMed     Abstract available


  51. XU J, He T, Wu Y, Cao J, et al
    VATS Versus Open Lobectomy in Pathological T1 SCLC: A Multi-Center Retrospective Analysis.
    Clin Lung Cancer. 2022;23:170-176.
    PubMed     Abstract available


  52. ZHANG S, Li S, Liu J, Yang C, et al
    Comparative Efficacy and Safety of TKIs Alone or in Combination With Antiangiogenic Agents in Advanced EGFR-Mutated NSCLC as the First-Line Treatment: A Systematic Review and Meta-Analysis.
    Clin Lung Cancer. 2022;23:159-169.
    PubMed     Abstract available


    February 2022
  53. PAYNE RG, Anker CJ, Sprague BL, No HJ, et al
    Active Surveillance for Early Stage Lung Cancer.
    Clin Lung Cancer. 2022 Feb 12. pii: S1525-7304(22)00012.
    PubMed     Abstract available


  54. JAZIEH AR, Saglam EK, Onal HC, Abdelkader Y, et al
    Real-world Treatment Patterns and Outcomes in Stage III Non-small Cell Lung Cancer: Middle East and Africa - KINDLE Study.
    Clin Lung Cancer. 2022 Feb 11. pii: S1525-7304(22)00016.
    PubMed     Abstract available


  55. HARRIS JP, Fujimoto DK, Nagasaka M, Ku E, et al
    Controversies in Lung Cancer: Heterogeneity in Treatment Recommendations for Stage III NSCLC According to Disease Burden and Oncogenic Driver Alterations.
    Clin Lung Cancer. 2022 Feb 10. pii: S1525-7304(22)00015.
    PubMed     Abstract available


  56. KAUFFMANN-GUERRERO D, Walter J, Kovacs J, Sellmer L, et al
    The Role of Thoracic Surgery in Small Cell Lung Cancer - A Large Longitudinal Analysis (2002-2015) Based on Real-World Data.
    Clin Lung Cancer. 2022 Feb 4. pii: S1525-7304(22)00009.
    PubMed     Abstract available


  57. CORTOT A, Le X, Smit E, Viteri S, et al
    Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
    Clin Lung Cancer. 2022 Feb 4. pii: S1525-7304(22)00013.
    PubMed     Abstract available


  58. GOVINDAN R, Lind M, Insa A, Khan SA, et al
    Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2022 Feb 4. pii: S1525-7304(22)00011.
    PubMed     Abstract available


  59. IZANO MA, Tran N, Fu A, Toland L, et al
    Implementing Real-World RECIST-based Tumor Response Assessment in Patients With Metastatic Non-small Cell Lung Cancer.
    Clin Lung Cancer. 2022 Feb 3. pii: S1525-7304(22)00014.
    PubMed     Abstract available


    January 2022
  60. ALTAN M, Singhi EK, Worst M, Carter BW, et al
    Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2022 Jan 31. pii: S1525-7304(22)00006.
    PubMed     Abstract available


  61. MARMARELIS ME, Yang YX, Hwang WT, Mamtani R, et al
    Platinum Re-Exposure as a Non-Small Cell Lung Cancer (NSCLC) Treatment Strategy in the Age of Immunotherapy.
    Clin Lung Cancer. 2022 Jan 10. pii: S1525-7304(22)00005.
    PubMed     Abstract available


  62. STOKES WA, Xiong N, Liu Y, Higgins KA, et al
    Association of Operability With Post-Treatment Mortality in Early-Stage Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2022 Jan 10. pii: S1525-7304(22)00007.
    PubMed     Abstract available


  63. HAYASHI H, Nadal E, Gray JE, Ardizzoni A, et al
    Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations.
    Clin Lung Cancer. 2022;23:e69-e82.
    PubMed     Abstract available


  64. LI Y, Wang K, Tian P, Li W, et al
    Acquired MET-DSTN Fusion Mediated Resistance to EGFR-TKIs in Lung Adenocarcinoma and Responded to Crizotinib Plus Gefitinib: A Case Report.
    Clin Lung Cancer. 2022;23:e83-e86.
    PubMed    


  65. HIRSCH FR, Walker J, Higgs BW, Cooper ZA, et al
    The Combiome Hypothesis: Selecting Optimal Treatment for Cancer Patients.
    Clin Lung Cancer. 2022;23:1-13.
    PubMed     Abstract available


  66. LECLAIR JN, Merl MY, Cohenuram M, Luon D, et al
    Real-World Incidence of Pneumonitis in Patients Receiving Durvalumab.
    Clin Lung Cancer. 2022;23:34-42.
    PubMed     Abstract available


  67. SCHMID S, Zhan L, Dietrich K, Khan K, et al
    Treatment Patterns and Outcomes of Patients With Advanced Pleural Mesothelioma at an Academic Referral Centre.
    Clin Lung Cancer. 2022;23:e43-e53.
    PubMed     Abstract available


  68. CAREY ET, Ferreira V, Shum E, Zhou F, et al
    The Common Thread: A Case of Synchronous Lung Cancers and a Germline CHEK2 Mutation.
    Clin Lung Cancer. 2022;23:e1-e4.
    PubMed     Abstract available


    December 2021
  69. ZHANG L, Yang X, Ming Z, Shi J, et al
    Molecular Characteristics of the Uncommon EGFR Exon 21 T854A Mutation and Response to Osimertinib in Patients With Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Dec 24. pii: S1525-7304(21)00304.
    PubMed     Abstract available


  70. HIJMERING-KAPPELLE LBM, Hiltermann TJN, Bensch F
    Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer During the COVID-19 Pandemic.
    Clin Lung Cancer. 2021 Dec 24. pii: S1525-7304(21)00305.
    PubMed     Abstract available


  71. LOGTENBERG ME, Tomlow B, Kastelijn EA, Schramel FMNH, et al
    Benefit of Concurrent Versus Sequential Chemoradiotherapy in Elderly Patients With Stage III Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Dec 17. pii: S1525-7304(21)00291.
    PubMed     Abstract available


  72. AKHTAR A, Sosa E, Castro S, Sur M, et al
    A Lung Cancer Screening Education Program Impacts both Referral Rates and Provider and Medical Assistant Knowledge at Two Federally Qualified Health Centers.
    Clin Lung Cancer. 2021 Dec 12. pii: S1525-7304(21)00289.
    PubMed     Abstract available


  73. YAGA M, Shiroyama T, Hirata H, Oya K, et al
    Lipoid Pneumonia After Pembrolizumab Treatment for Advanced Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2021 Dec 10. pii: S1525-7304(21)00290.
    PubMed    


  74. KEE W, Ng KYY, Lee JJX, Tan DSW, et al
    Myasthenia Gravis and Myocarditis After Administration of Pembrolizumab in a Patient With Metastatic Non-small Cell Lung Cancer and Resected Thymoma.
    Clin Lung Cancer. 2021 Dec 10. pii: S1525-7304(21)00288.
    PubMed    


    November 2021
  75. GANESH A, Katipally R, Pasquinelli M, Feldman L, et al
    Increased Disparities in Patients Diagnosed with Metastatic Lung Cancer Following Lung CT Screening in the United States.
    Clin Lung Cancer. 2021 Nov 25. pii: S1525-7304(21)00287.
    PubMed     Abstract available


  76. HEYNEMANN S, Yu H, Churilov L, Rivalland G, et al
    NaPi2b expression in a large surgical Non-Small Cell Lung Cancer (NSCLC) cohort.
    Clin Lung Cancer. 2021 Nov 16. pii: S1525-7304(21)00281.
    PubMed     Abstract available


  77. ALDIN MK, Qi L, Zhou X, Kahn LA, et al
    Detection of second primary lung cancers on surveillance imaging following stereotactic ablative radiotherapy for non-small cell lung cancer.
    Clin Lung Cancer. 2021 Nov 11. pii: S1525-7304(21)00280.
    PubMed     Abstract available


  78. CATANIA C, Muthusamy B, Spitaleri G, Del Signore E, et al
    The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature.
    Clin Lung Cancer. 2021 Nov 11. pii: S1525-7304(21)00279.
    PubMed     Abstract available


  79. HOCHMAIR MJ, Illini O, Prosch H, Krenbek D, et al
    Complete Remission to Afatinib in a Patient Harboring a Novel Epidermal Growth Factor Mutation in De Novo Small-Cell Lung Cancer: A Case Report: Clinical Lung Cancer.
    Clin Lung Cancer. 2021 Nov 10. pii: S1525-7304(21)00277.
    PubMed    


  80. SUVEG K, Le Pechoux C, Faivre-Finn C, Putora PM, et al
    Role of Postoperative Radiotherapy in the Management for Resected NSCLC - Decision Criteria in Clinical Routine Pre- and Post-LungART.
    Clin Lung Cancer. 2021;22:579-586.
    PubMed     Abstract available


  81. WATERHOUSE DM, Tseng WY, Espirito JL, Robert NJ, et al
    Understanding Contemporary Molecular Biomarker Testing Rates and Trends for Metastatic NSCLC Among Community Oncologists.
    Clin Lung Cancer. 2021;22:e901-e910.
    PubMed     Abstract available


  82. WANG B, Hamal P, Sun K, Bhuva MS, et al
    Clinical Value and Pathologic Basis of Cystic Airspace Within Subsolid Nodules Confirmed as Lung Adenocarcinomas by Surgery.
    Clin Lung Cancer. 2021;22:e881-e888.
    PubMed     Abstract available


  83. WANG CY, Hsia JY, Li CH, Ho CC, et al
    Lung Adenocarcinoma With Primary LIMD1-BRAF Fusion Treated With MEK Inhibitor: A Case Report.
    Clin Lung Cancer. 2021;22:e878-e880.
    PubMed    


  84. CLEMENT MS, Ebert EBF, Meldgaard P, Sorensen BS, et al
    Co-occurring MET Amplification Predicts Inferior Clinical Response to First-Line Erlotinib in Advanced Stage EGFR-Mutated NSCLC Patients.
    Clin Lung Cancer. 2021;22:e870-e877.
    PubMed     Abstract available


  85. YU J, Du Y, Mekhail T, Socinski MA, et al
    Adverse Overall Survival Impact of PD-L1 Positivity in Patients With KRAS G12C Mutation Is Abolished by the Immunotherapy.
    Clin Lung Cancer. 2021;22:e856-e858.
    PubMed    


  86. JI J, Mitra A, Camidge DR, Riess JW, et al
    Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib.
    Clin Lung Cancer. 2021;22:e851-e855.
    PubMed    


  87. FURUTA H, Kato S, Masago K, Hida T, et al
    Palmoplantar Pustulosis Caused by Immune-Checkpoint Inhibitors.
    Clin Lung Cancer. 2021;22:e829-e832.
    PubMed    


  88. SHIGENOBU T, Takahashi Y, Masugi Y, Hanawa R, et al
    Micropapillary Predominance Is a Risk Factor for Brain Metastasis in Resected Lung Adenocarcinoma.
    Clin Lung Cancer. 2021;22:e820-e828.
    PubMed     Abstract available


  89. CECCHI C, Mariniello A, Carnio S, Delcuratolo MD, et al
    Black Hairy Tongue After Immune Checkpoint Inhibitors in NSCLC: A Case Report and Review of the Literature.
    Clin Lung Cancer. 2021;22:e804-e807.
    PubMed    


    October 2021
  90. XIAOBING L, Meipan Y, Pengfei X, Yue Z, et al
    Bronchial Artery Chemoembolization for Hemoptysis in Advanced Primary Lung Cancer.
    Clin Lung Cancer. 2021 Oct 29. pii: S1525-7304(21)00272.
    PubMed     Abstract available


  91. SHIRAISHI Y, Hakozaki T, Nomura S, Kataoka T, et al
    A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non-Small Cell Lung Cancer Without Driver Gene A
    Clin Lung Cancer. 2021 Oct 25. pii: S1525-7304(21)00271.
    PubMed     Abstract available


  92. GARON EB, Peterson P, Rizzo MT, Kim JS, et al
    Overall Survival and Safety With Pemetrexed/Platinum +/- Anti-VEGF Followed by Pemetrexed +/- Anti-VEGF Maintenance in Advanced Nonsquamous Non-Small-Cell Lung Cancer: A Pooled Analysis of 4 Randomized Studies.
    Clin Lung Cancer. 2021 Oct 25. pii: S1525-7304(21)00274.
    PubMed     Abstract available


  93. SONODA D, Matsuura Y, Kondo Y, Ichinose J, et al
    A Reasonable Definition of Oligo-Recurrence in Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2021 Oct 25. pii: S1525-7304(21)00276.
    PubMed     Abstract available


  94. DOYEN J, Besse B, Texier M, Bonnet N, et al
    PD-1 iNhibitor and chemotherapy with concurrent IRradiation at VAried tumor sites in advanced Non-small cell lung cAncer: the Prospective Randomized Phase 3 NIRVANA-Lung Trial.
    Clin Lung Cancer. 2021 Oct 24. pii: S1525-7304(21)00269.
    PubMed     Abstract available


  95. HARATAKE N, Hayashi H, Shimokawa M, Nakano Y, et al
    Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L).
    Clin Lung Cancer. 2021 Oct 24. pii: S1525-7304(21)00270.
    PubMed     Abstract available


  96. LI J, Wang Y, Li J, Cao S, et al
    Meta-analysis of Lobectomy and Sublobar Resection for Stage I Non-small Cell Lung Cancer With Spread Through Air Spaces.
    Clin Lung Cancer. 2021 Oct 23. pii: S1525-7304(21)00268.
    PubMed     Abstract available


  97. HELLYER JA, White MN, Gardner RM, Cunanan K, et al
    Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer.
    Clin Lung Cancer. 2021 Oct 21. pii: S1525-7304(21)00245.
    PubMed     Abstract available


  98. NAGASAKA M, Singh V, Baca Y, Sukari A, et al
    The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Oct 18. pii: S1525-7304(21)00244.
    PubMed     Abstract available


  99. HIRSCH FR, Redman MW, Moon J, Agustoni F, et al
    EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCL
    Clin Lung Cancer. 2021 Oct 10. pii: S1525-7304(21)00263.
    PubMed     Abstract available


  100. SUDA K, Ohara S, Fujino T, Hamada A, et al
    Frequent EGFR Mutations and Better Prognosis in Positron Emission Tomography-Negative, Solid-Type Lung Cancer.
    Clin Lung Cancer. 2021 Oct 10. pii: S1525-7304(21)00264.
    PubMed     Abstract available


  101. PAGE RD, Drusbosky LM, Dada H, Raymond VM, et al
    Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Oct 10. pii: S1525-7304(21)00262.
    PubMed     Abstract available


  102. LELEU O, Basille D, Auquier M, Clarot C, et al
    Results of Second Round Lung Cancer Screening by Low-Dose CT scan - French Cohort Study (DEP-KP80).
    Clin Lung Cancer. 2021 Oct 10. pii: S1525-7304(21)00261.
    PubMed     Abstract available


  103. HEYMACH JV, Mitsudomi T, Harpole D, Aperghis M, et al
    Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab+Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN
    Clin Lung Cancer. 2021 Oct 10. pii: S1525-7304(21)00265.
    PubMed     Abstract available


  104. YAMASAKI N, Kim YH, Iwatsubo S, Nishimura Y, et al
    Role of Postoperative Radiotherapy in Patients With Completely Resected pIIIA-N2 Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Oct 2. pii: S1525-7304(21)00249.
    PubMed    


    September 2021
  105. KUEHNE N, Hueniken K, Xu M, Shakik S, et al
    Longitudinal Assessment of Health Utility Scores, Symptoms and Toxicities in Patients with Small Cell Lung Cancer Using Real World Data.
    Clin Lung Cancer. 2021 Sep 25. pii: S1525-7304(21)00247.
    PubMed     Abstract available


  106. NAKAO M, Saji H, Mun M, Nakamura H, et al
    Prognostic Impact of Mediastinal Lymph Node Dissection in Octogenarians With Lung Cancer: JACS1303.
    Clin Lung Cancer. 2021 Sep 24. pii: S1525-7304(21)00248.
    PubMed     Abstract available


  107. TU HY, Li YS, Bai XY, Sun YL, et al
    Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.
    Clin Lung Cancer. 2021 Sep 20. pii: S1525-7304(21)00242.
    PubMed     Abstract available


  108. SAKAGUCHI T, Kokubo Y, Furuhashi K, Nakamura Y, et al
    An Extensive-stage Small-cell Lung Cancer Case With Preexisting Lambert-Eaton Myasthenic Syndrome Successfully Treated With an Immune Checkpoint Inhibitor.
    Clin Lung Cancer. 2021 Sep 17. pii: S1525-7304(21)00241.
    PubMed    


  109. HAO Z, Sekkath Veedu J
    Current Strategies for Extensive Stage Small Cell Lung Cancer Beyond First-line Therapy.
    Clin Lung Cancer. 2021 Sep 17. pii: S1525-7304(21)00243.
    PubMed     Abstract available


  110. LI X, Sun J, Wang L
    NF1-Mutant Cancer and Immune Checkpoint Inhibitors: A Large Database Analysis.
    Clin Lung Cancer. 2021;22:480-481.
    PubMed    


  111. ALTAN M, Patel AB
    Management of Cutaneous Immunotherapy Toxicities.
    Clin Lung Cancer. 2021;22:e783.
    PubMed    


  112. HUANG WL, Liu YW
    The Role of Stereotactic Body Radiation Therapy for Pulmonary Carcinosarcoma.
    Clin Lung Cancer. 2021;22:e684-e685.
    PubMed    


  113. NASSER A, Baird A, Saint-Pierre MD, Amjadi K, et al
    Three Decades of Malignant Pleural Mesothelioma: An Academic Center Experience.
    Clin Lung Cancer. 2021;22:441-448.
    PubMed     Abstract available


  114. VEKENS K, Everaert H, Neyns B, Ilsen B, et al
    The Value of (18)F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression.
    Clin Lung Cancer. 2021;22:432-440.
    PubMed     Abstract available


  115. LIM JU
    Management of Oligometastasis and Oligoprogression in Patients with Epidermal Growth Factor Receptor Mutation-Positive NSCLC in the Era of Third-Generation Tyrosine Kinase Inhibitors.
    Clin Lung Cancer. 2021;22:e786-e792.
    PubMed     Abstract available


  116. TAKAO T, Tanaka K, Shiraishi Y, Ota K, et al
    Osimertinib-induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone.
    Clin Lung Cancer. 2021;22:e784-e785.
    PubMed    


  117. GILES AE, Teferi Y, Kidane B, Bayaraa B, et al
    Lung Resection Without Tissue Diagnosis: A Pragmatic Perspective on the Indeterminate Pulmonary Nodule.
    Clin Lung Cancer. 2021;22:e774-e781.
    PubMed     Abstract available


  118. PERNA M, Scotti V, Ciammella P, Borghetti P, et al
    The NIPRO Study: An Observational, Retrospective, Multicenter Study on the Safety of the Radiotherapy and Immunotherapy Combination for Advanced-Stage NSCLC.
    Clin Lung Cancer. 2021;22:e767-e773.
    PubMed     Abstract available


  119. LEONETTI A, Minari R, Boni L, Gnetti L, et al
    Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial.
    Clin Lung Cancer. 2021;22:473-477.
    PubMed     Abstract available


  120. LIN G, Liu Y, Li H, Chen S, et al
    Emergence of NOTCH2-NTRK1 After Osimertinib in a Patient With Lung Adenocarcinoma With Neuroendocrine Differentiation.
    Clin Lung Cancer. 2021;22:e712-e715.
    PubMed    


  121. HARADA G, Amano MT, Antonacio FF, Behar MH, et al
    Dramatic Response to Pembrolizumab Monotherapy in a Patient With ARID1A-Mutant Lung Adenocarcinoma: Case Report.
    Clin Lung Cancer. 2021;22:e708-e711.
    PubMed     Abstract available


  122. FROST N, Kollmeier J, Misch D, Vollbrecht C, et al
    Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (>/= 50%) NSCLC: Real-world Results with Special Focus on PS >/= 2, Brain Metastases, and Steroids.
    Clin Lung Cancer. 2021;22:411-422.
    PubMed     Abstract available


  123. ZHANG Y, Wang H, Wang X, Li S, et al
    Precision Treatment of Advanced Lung Adenocarcinoma With Coexisting EGFR, ALK, and ROS1 Mutations: A Case Report.
    Clin Lung Cancer. 2021;22:e699-e702.
    PubMed    


  124. WADDINGTON T, Mambetsariev I, Pharaon R, Fricke J, et al
    Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report.
    Clin Lung Cancer. 2021;22:e703-e707.
    PubMed    


  125. DOUBRE H, Fraboulet S, Longchampt E, Damotte D, et al
    ALK Rearrangement in Lung Neuroendocrine Neoplasms: Case Series of Non-Asian Patients With Response to ALK Inhibitors.
    Clin Lung Cancer. 2021;22:e686-e690.
    PubMed    


  126. AREDO JV, Diehn M, Berry GJ, Wakelee HA, et al
    Targeted Treatment of Multiple Primary Lung Cancers Harboring Distinct EGFR or RET Alterations: A Case Report.
    Clin Lung Cancer. 2021;22:e673-e677.
    PubMed    


  127. DAVIS A, Mahar A, Wong K, Barnet M, et al
    Prolonged Disease Control on Nivolumab for Primary Pulmonary NUT Carcinoma.
    Clin Lung Cancer. 2021;22:e665-e667.
    PubMed    


    August 2021
  128. MYNARD N, Saxena A, Mavracick A, Port J, et al
    Lung Cancer Stage Shift as a Result of COVID-19 Lockdowns in New York City, a Brief Report.
    Clin Lung Cancer. 2021 Aug 29. pii: S1525-7304(21)00214.
    PubMed     Abstract available


  129. JIN Y, Xue Q, Shen X, Zheng Q, et al
    PD-L1 Expression and Comprehensive Molecular Profiling Predict Survival in Nonsmall Cell Lung Cancer: A Real-World Study of a Large Chinese Cohort.
    Clin Lung Cancer. 2021 Aug 28. pii: S1525-7304(21)00213.
    PubMed     Abstract available


  130. SEITLINGER J, Prieto M, Guerrera F, Streit A, et al
    Neutrophil-to-lymphocyte ratio is correlated to driver gene mutations in surgically-resected non-small cell lung cancer and its post-operative evolution impacts outcomes.
    Clin Lung Cancer. 2021 Aug 22. pii: S1525-7304(21)00205.
    PubMed     Abstract available


  131. WOODARD GA, Kratz JR, Haro G, Gubens MA, et al
    Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy.
    Clin Lung Cancer. 2021 Aug 20. pii: S1525-7304(21)00212.
    PubMed     Abstract available


  132. TAKADA K, Takamori S, Miura N, Shikada Y, et al
    Comments on 'The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors'.
    Clin Lung Cancer. 2021 Aug 10. pii: S1525-7304(21)00208.
    PubMed    


  133. LEE M, Patel D, Jofre S, Fidvi S, et al
    Large Cell Neuroendocrine Carcinoma Transformation as a Mechanism of Acquired Resistance to Osimertinib in Non-small Cell Lung Cancer: Case Report and Literature Review.
    Clin Lung Cancer. 2021 Aug 10. pii: S1525-7304(21)00206.
    PubMed    


    July 2021
  134. LI X, Chen X, He S, Chen H, et al
    The Application of Pigtail Catheters in Postoperative Drainage of Lung Cancer.
    Clin Lung Cancer. 2021 Jul 31. pii: S1525-7304(21)00191.
    PubMed     Abstract available


  135. REUSS JE, Gosa L, Liu SV
    Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments.
    Clin Lung Cancer. 2021 Jul 25. pii: S1525-7304(21)00192.
    PubMed     Abstract available


  136. GJYSHI O, Lin SH, Pezzi TA, Ning MS, et al
    Care Patterns for Stereotactic Radiosurgery in Small Cell Lung Cancer Brain Metastases.
    Clin Lung Cancer. 2021 Jul 24. pii: S1525-7304(21)00184.
    PubMed     Abstract available


  137. UMEMURA S, Chen V, Chahine JJ, Kallakury B, et al
    Arginase Pathway Markers of Immune-Microenvironment in Thymic Epithelial Tumors and Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Jul 20. pii: S1525-7304(21)00187.
    PubMed     Abstract available


  138. WONG DJ, Bauer TM, Gordon MS, Bene-Tchaleu F, et al
    Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Results From a Phase 1b Trial.
    Clin Lung Cancer. 2021 Jul 20. pii: S1525-7304(21)00183.
    PubMed     Abstract available


  139. SINGH S, Pavesi F, Steiling K, Asokan S, et al
    Risk Factors for Lung Cancer in an Underrepresented Safety-Net Screening Cohort.
    Clin Lung Cancer. 2021 Jul 19. pii: S1525-7304(21)00190.
    PubMed     Abstract available


  140. DE RUYSSCHER D, Ramalingam S, Urbanic J, Gerber DE, et al
    CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-S
    Clin Lung Cancer. 2021 Jul 19. pii: S1525-7304(21)00186.
    PubMed     Abstract available


  141. TAKAMORI S, Takada K, Shimokawa M, Okamoto T, et al
    Comments on "Lobe-specific Lymph Node Dissection in Clinical Stage IA Solid-dominant Non-small-cell Lung Cancer: A Propensity Score Matching Study".
    Clin Lung Cancer. 2021 Jul 7. pii: S1525-7304(21)00181.
    PubMed    


  142. MANGLAVITI S, Brambilla M, Signorelli D, Ferrara R, et al
    Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology.
    Clin Lung Cancer. 2021 Jul 5. pii: S1525-7304(21)00180.
    PubMed     Abstract available


  143. KOOPMAN B, Groen HJM, Schuuring E, Hiltermann TJN, et al
    Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature.
    Clin Lung Cancer. 2021 Jul 3. pii: S1525-7304(21)00178.
    PubMed     Abstract available


  144. TSUI DCC, Aisner D, Nijmeh H, Bao L, et al
    Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy.
    Clin Lung Cancer. 2021 Jul 3. pii: S1525-7304(21)00179.
    PubMed    


  145. YIN J, Xi J, Liang J, Zhan C, et al
    Solid Components in the Mediastinal Window of Computed Tomography Define a Distinct Subtype of Subsolid Nodules in Clinical Stage I Lung Cancers.
    Clin Lung Cancer. 2021;22:324-331.
    PubMed     Abstract available


  146. KIM ES, Kish JK, Cseh A, Moehring B, et al
    Second-line Afatinib or Chemotherapy Following Immunochemotherapy for the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: Real-world Effectiveness and Safety From a Multisite Retrospective Chart Review in the USA.
    Clin Lung Cancer. 2021;22:292-300.
    PubMed     Abstract available


  147. SHIRASAWA M, Yoshida T, Takayanagi D, Shiraishi K, et al
    Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma.
    Clin Lung Cancer. 2021;22:282-291.
    PubMed     Abstract available


  148. TAKEDA M, Shimokawa M, Nakamura A, Nosaki K, et al
    A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-
    Clin Lung Cancer. 2021;22:376-380.
    PubMed     Abstract available


  149. RAMALINGAM S, Dinan MA, Crawford J
    Treatment at Integrated Centers Might Bridge the Academic-Community Survival Gap in Patients With Metastatic Non-Small Cell Carcinoma of the Lung.
    Clin Lung Cancer. 2021;22:e646-e653.
    PubMed     Abstract available


  150. LAU SCM, Fares AF, Le LW, Mackay KM, et al
    Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors.
    Clin Lung Cancer. 2021;22:253-259.
    PubMed     Abstract available


  151. NAAMAN R, Lautenschlaeger T, Diab K
    Feasibility of Performing Transvascular Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration.
    Clin Lung Cancer. 2021;22:e595-e601.
    PubMed     Abstract available


  152. TAYLOR M, Grant SW, West D, Shackcloth M, et al
    Ninety-Day Mortality: Redefining the Perioperative Period After Lung Resection.
    Clin Lung Cancer. 2021;22:e642-e645.
    PubMed     Abstract available


  153. REGNERY S, Eichkorn T, Weykamp F, Held T, et al
    Safety and Efficacy of Stereotactic Body Radiotherapy in Ultracentral Lung Tumors Using a Risk-optimized Fractionation Scheme.
    Clin Lung Cancer. 2021;22:332-340.
    PubMed     Abstract available


  154. RALKI M, Serrien A, Lambert J, Leys M, et al
    Brown-Sequard Syndrome in a Desmoplastic Malignant Mesothelioma Patient: A Rare Complication.
    Clin Lung Cancer. 2021;22:e552-e554.
    PubMed    


  155. LEE PH, Chang GC
    Transformations First Into Squamous-Cell Carcinoma and Later Into Sarcomatoid Carcinoma After Acquired Resistance to Osimertinib in a Patient With EGFR-Mutant Lung Adenocarcinoma: Case Report.
    Clin Lung Cancer. 2021;22:e536-e541.
    PubMed    


  156. TAO L, Miao R, Mekhail T, Sun J, et al
    Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma.
    Clin Lung Cancer. 2021;22:e506-e511.
    PubMed     Abstract available


  157. KERKHOFF JW, Vreuls W, Vermeer LC
    Mesothelioma Micronodular Metastasis Pattern Confirmed by Transbronchial Cryobiopsy: Case Report.
    Clin Lung Cancer. 2021;22:e533-e535.
    PubMed    


  158. CORTINOVIS D, Grosso F, Carlucci L, Zucali PA, et al
    Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study.
    Clin Lung Cancer. 2021;22:361-370.
    PubMed     Abstract available


  159. SASSOROSSI C, Lococo F, Pogliani L, Tabacco D, et al
    Factors Affecting Long-Term Survival in Locally Advanced NSCLC Patients With Pathologic Complete Response After Induction Therapy Followed by Surgical Resection.
    Clin Lung Cancer. 2021;22:e542-e543.
    PubMed    


    June 2021
  160. YU HA, Goldberg SB, Le X, Piotrowska Z, et al
    Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD).
    Clin Lung Cancer. 2021 Jun 25. pii: S1525-7304(21)00157.
    PubMed     Abstract available


  161. YANG Y, Deng L, Yang Y, Zhang T, et al
    Efficacy and Safety of Combined Brain Radiotherapy and Immunotherapy in Non-Small-Cell Lung Cancer With Brain Metastases: A Systematic Review and Meta-Analysis.
    Clin Lung Cancer. 2021 Jun 24. pii: S1525-7304(21)00160.
    PubMed     Abstract available


  162. JACOBS CD, Mehta K, Gao J, Wang X, et al
    Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Jun 24. pii: S1525-7304(21)00159.
    PubMed     Abstract available


  163. BARTA JA, Shusted CS, Ruane B, Pimpinelli M, et al
    Racial Differences in Lung Cancer Screening Beliefs and Screening Adherence.
    Clin Lung Cancer. 2021 Jun 13. pii: S1525-7304(21)00143.
    PubMed     Abstract available


  164. SAITO G, Kono M, Koyanagi Y, Miyashita K, et al
    Significance of Brain Imaging for Staging in Patients With Clinical Stage T1-2 N0 Non-Small-Cell Lung Cancer on Positron Emission Tomography/Computed Tomography.
    Clin Lung Cancer. 2021 Jun 13. pii: S1525-7304(21)00145.
    PubMed     Abstract available


  165. PINQUIE F, Cortot AB, Chevalier LM, Morel A, et al
    A Case Report of Successful Treatment With Crizotinib to Overcome Resistance to Osimertinib in an EGFR Mutated Non-Small-Cell Lung Cancer Patient Harboring an Acquired MET Exon 14 Mutation.
    Clin Lung Cancer. 2021 Jun 13. pii: S1525-7304(21)00142.
    PubMed    


  166. TSUI DCC, Kavanagh BD, Honce JM, Rossi C, et al
    Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on Pralsetinib.
    Clin Lung Cancer. 2021 Jun 12. pii: S1525-7304(21)00148.
    PubMed    


  167. HENDRIKS LEL, Remon J, Besse B
    Dorian Gray Syndrome of Upfront Immunotherapy in Patients With Non-Small-Cell Lung Cancer and High PD-L1 Expression.
    Clin Lung Cancer. 2021 Jun 12. pii: S1525-7304(21)00149.
    PubMed    


  168. SOCINSKI MA, Ozguroglu M, Villegas A, Daniel D, et al
    Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).
    Clin Lung Cancer. 2021 Jun 12. pii: S1525-7304(21)00144.
    PubMed     Abstract available


    May 2021
  169. GADGEEL S, Hirsch FR, Kerr K, Barlesi F, et al
    Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
    Clin Lung Cancer. 2021 May 30. pii: S1525-7304(21)00101.
    PubMed     Abstract available


  170. LI Y, Zhang Y, Jia X, Jiang P, et al
    Effect of Immune-Related Adverse Events and Pneumonitis on Prognosis in Advanced Non-Small Cell Lung Cancer: A Comprehensive Systematic Review and Meta-analysis.
    Clin Lung Cancer. 2021 May 28. pii: S1525-7304(21)00098.
    PubMed     Abstract available


  171. LEAL JL, Alexander M, Itchins M, Wright GM, et al
    EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 May 16. pii: S1525-7304(21)00093.
    PubMed     Abstract available


  172. RIESS JW, Reckamp KL, Frankel P, Longmate J, et al
    Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878).
    Clin Lung Cancer. 2021 May 15. pii: S1525-7304(21)00094.
    PubMed     Abstract available


  173. RIESS JW, Rolfo C, Gandara DR
    Novel Clinical Trial Designs in Pursuit of Precision Oncology: Lung-MAP As a Model.
    Clin Lung Cancer. 2021;22:153-155.
    PubMed    


  174. PRINZI N, Rossi RE, Proto C, Leuzzi G, et al
    Recent Advances in the Management of Typical and Atypical Lung Carcinoids.
    Clin Lung Cancer. 2021;22:161-169.
    PubMed     Abstract available


  175. WHITE MN, Piotrowska Z, Stirling K, Liu SV, et al
    Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression.
    Clin Lung Cancer. 2021;22:201-209.
    PubMed     Abstract available


  176. SAMUEL E, Lie G, Balasubramanian A, Hiong A, et al
    Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC.
    Clin Lung Cancer. 2021;22:e425-e430.
    PubMed     Abstract available


  177. GADOTTI LL, Nogueira Amorim Canedo FS, Ribeiro MFSA, Sacardo KP, et al
    Successful Drug Rechallenge Following Severe Acute Alectinib-induced Interstitial Lung Disease in a Patient With Advanced ALK-rearranged Lung Adenocarcinoma.
    Clin Lung Cancer. 2021;22:e481-e486.
    PubMed    


  178. ZENG YW, Liu Y, Qi Y, Yin MP, et al
    Bronchial Arterial Infusion Chemotherapy Plus Drug-eluting Bead Chemoembolization for Recurrence of Carina Region-induced Severe Right Main Bronchial Stenosis After Pneumonectomy.
    Clin Lung Cancer. 2021;22:e293-e297.
    PubMed    


  179. BEHRENS C, Rocha P, Parra ER, Feng L, et al
    Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma.
    Clin Lung Cancer. 2021;22:e415-e424.
    PubMed     Abstract available


  180. PENG LP
    Regarding: MicroRNA-126 Targeting PIK3R2 Inhibits NSCLC A549 Cell Proliferation, Migration, and Invasion by Regulation of PTEN/PI3K/AKT Pathway.
    Clin Lung Cancer. 2021;22:e446-e450.
    PubMed    


  181. CHAPMAN BV, Ning MS, Farnia B, Mesko S, et al
    Postoperative Radiotherapy for Locally Advanced NSCLC: Implications for Shifting to Conformal, High-Risk Fields.
    Clin Lung Cancer. 2021;22:225-233.
    PubMed     Abstract available


  182. PATEL A, Roshkovan L, McNulty S, Alley E, et al
    Delayed-Phase Enhancement for Evaluation of Malignant Pleural Mesothelioma on Computed Tomography: A Prospective Cohort Study.
    Clin Lung Cancer. 2021;22:210-217.
    PubMed     Abstract available


  183. XIE Z, Gu Y, Xie X, Lin X, et al
    Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance.
    Clin Lung Cancer. 2021;22:e390-e394.
    PubMed    


  184. KOZLOV A, Pantel A, Iagaru A, Ikeda D, et al
    Pulmonary Adenocarcinoma Metastasis to the Breast Unexpectedly Discovered on Re-staging (18)F-FDG PET/CT in a Woman With a Normal Screening Mammogram.
    Clin Lung Cancer. 2021;22:e438-e441.
    PubMed    


  185. COUDERC AL, Tomasini P, Nouguerede E, Rey D, et al
    Older Patients Treated for Lung and Thoracic Cancers: Unplanned Hospitalizations and Overall Survival.
    Clin Lung Cancer. 2021;22:e405-e414.
    PubMed     Abstract available


  186. TSUTANI Y, Nakayama H, Ito H, Handa Y, et al
    Long-Term Outcomes After Sublobar Resection Versus Lobectomy in Patients With Clinical Stage IA Lung Adenocarcinoma Meeting the Node-Negative Criteria Defined by High-Resolution Computed Tomography and [(18)F]-Fluoro-2-Deoxy-d-Glucose Positron Emissio
    Clin Lung Cancer. 2021;22:e431-e437.
    PubMed     Abstract available


  187. KANDER EM, Shah MH, Zhou Y, Goyal A, et al
    Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid.
    Clin Lung Cancer. 2021;22:e442-e445.
    PubMed    


  188. KUNTE S, Stevenson J
    A Case of HLA-DRB1-MET Rearranged Lung Adenocarcinoma With Rapid Response to Crizotinib.
    Clin Lung Cancer. 2021;22:e298-e300.
    PubMed    


  189. WANG S, Wu X, Zhao J, Chen H, et al
    Next-Generation Sequencing Identified a Novel Crizotinib-Sensitive PLB1-ALK Rearrangement in Lung Large-Cell Neuroendocrine Carcinoma.
    Clin Lung Cancer. 2021;22:e366-e370.
    PubMed    


  190. TAMIYA A, Isa SI, Taniguchi Y, Nakagawa H, et al
    Prospective Observational Study of Treatment Resistance-related Gene Screening Using Plasma Circulating Tumor DNA in Third-generation EGFR-TKI Osimertinib Therapy (Elucidator).
    Clin Lung Cancer. 2021;22:e336-e341.
    PubMed     Abstract available


  191. ZHOU M, Joshi N, Raj KP, Wakelee H, et al
    PD-1/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review.
    Clin Lung Cancer. 2021;22:e329-e335.
    PubMed    


    April 2021
  192. HAMADA A, Soh J, Hata A, Nakamatsu K, et al
    Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non-small-cell Lung Cancer: SQUAT trial (WJOG 12119L).
    Clin Lung Cancer. 2021 Apr 27. pii: S1525-7304(21)00090.
    PubMed     Abstract available


  193. OYANAGI J, Koh Y, Sato K, Teraoka S, et al
    Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors.
    Clin Lung Cancer. 2021 Apr 27. pii: S1525-7304(21)00091.
    PubMed     Abstract available


  194. BYERS LA, Navarro A, Schaefer E, Johnson M, et al
    A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer.
    Clin Lung Cancer. 2021 Apr 24. pii: S1525-7304(21)00089.
    PubMed     Abstract available


  195. FISHER A, Kim S, Farhat D, Belzer K, et al
    Risk Factors Associated with a Second Primary Lung Cancer in Patients with an Initial Primary Lung Cancer.
    Clin Lung Cancer. 2021 Apr 23. pii: S1525-7304(21)00088.
    PubMed     Abstract available


  196. MERKHOFER CM, Eaton KD, Martins RG, Ramsey SD, et al
    Impact of Clinical Trial Participation on Survival of Patients with Metastatic Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Apr 22. pii: S1525-7304(21)00087.
    PubMed     Abstract available


  197. RAEZ LE, Carracedo C, Drusbosky LM, Velez M, et al
    EGFR L718V (+)/T790M (-) as a Mechanism of Resistance in Patients with Metastatic Non-small-cell Lung Cancer with EGFR L858R Mutations.
    Clin Lung Cancer. 2021 Apr 9. pii: S1525-7304(21)00072.
    PubMed    


    March 2021
  198. MORAN A, Wang Y, Dyer BA, Yip SSF, et al
    Prognostic Value of Computed Tomography and/or (18)F-Fluorodeoxyglucose Positron Emission Tomography Radiomics Features in Locally Advanced Non-small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Mar 27. pii: S1525-7304(21)00069.
    PubMed     Abstract available


  199. ARRIETA O, Varela-Santoyo E, Cardona AF, Sanchez-Reyes R, et al
    Association of Carcinoembryonic Antigen Reduction With Progression-free and Overall Survival Improvement in Advanced Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2021 Mar 27. pii: S1525-7304(21)00068.
    PubMed     Abstract available


  200. KAO C, Powers E, Wu Y, Datto MB, et al
    Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Clin Lung Cancer. 2021 Mar 27. pii: S1525-7304(21)00071.
    PubMed     Abstract available


  201. SHEN Q, Kalyani FS, Qu J, Chen Z, et al
    A Case of Small Cell Lung Carcinoma Harboring an EML4-ALK Fusion with Partial Response to Crizotinib.
    Clin Lung Cancer. 2021 Mar 26. pii: S1525-7304(21)00066.
    PubMed    


  202. WEISS J, Goldschmidt J, Andric Z, Dragnev KH, et al
    Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.
    Clin Lung Cancer. 2021 Mar 26. pii: S1525-7304(21)00064.
    PubMed     Abstract available


  203. BRAINSON CF, Huang B, Chen Q, McLouth LE, et al
    Description of a Lung Cancer Hotspot: Disparities in Lung Cancer Histology, Incidence, and Survival in Kentucky and Appalachian Kentucky.
    Clin Lung Cancer. 2021 Mar 26. pii: S1525-7304(21)00061.
    PubMed     Abstract available


  204. KELLER A, Ghanta S, Rodriguez-Lopez JL, Patel A, et al
    Utility of Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer in the MRI Screening Era.
    Clin Lung Cancer. 2021 Mar 26. pii: S1525-7304(21)00063.
    PubMed     Abstract available


  205. CABEZON-GUTIERREZ L, Custodio-Cabello S, Palka-Kotlowska M, Alonso-Viteri S, et al
    Biomarkers of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Beyond PD-L1.
    Clin Lung Cancer. 2021 Mar 24. pii: S1525-7304(21)00060.
    PubMed     Abstract available


  206. DALL'OLIO FG, Gelsomino F, Conci N, Marcolin L, et al
    PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
    Clin Lung Cancer. 2021 Mar 16. pii: S1525-7304(21)00057.
    PubMed     Abstract available


  207. UPRETY D
    CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma.
    Clin Lung Cancer. 2021;22:71-73.
    PubMed    


  208. TAKEYASU Y, Yoshida T, Shibaki R, Matsumoto Y, et al
    Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS >/= 50%) NSCLC.
    Clin Lung Cancer. 2021;22:127-133.
    PubMed     Abstract available


  209. MOUNTZIOS G, de Toma A, Economopoulou P, Friedlaender A, et al
    Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy.
    Clin Lung Cancer. 2021;22:e180-e192.
    PubMed     Abstract available


  210. ZHANG C, He Z, Cheng J, Cao J, et al
    Surgical Outcomes of Lobectomy Versus Limited Resection for Clinical Stage I Ground-Glass Opacity Lung Adenocarcinoma 2 Centimeters or Smaller.
    Clin Lung Cancer. 2021;22:e160-e168.
    PubMed     Abstract available


  211. SHAH R, Klotz LV, Chung I, Feisst M, et al
    A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol.
    Clin Lung Cancer. 2021;22:142-146.
    PubMed     Abstract available


  212. LIN G, Liu Y, Li H, Chen S, et al
    Emergence of NOTCH2-NTRK1 After Osimertinib in a Patient With Lung Adenocarcinoma With Neuroendocrine Differentiation.
    Clin Lung Cancer. 2021;22:e157-e159.
    PubMed    


  213. SUDA K, Sakai K, Obata K, Ohara S, et al
    Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Non-Small Cell Lung Cancers: Analysis of Five Cases.
    Clin Lung Cancer. 2021;22:e141-e145.
    PubMed     Abstract available


    February 2021
  214. SATOH H, Miyazaki K, Kagohashi K
    Letter to the Editor Regarding "Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy".
    Clin Lung Cancer. 2021 Feb 27. pii: S1525-7304(21)00051.
    PubMed    


  215. GREGORC V, Mazzarella L, Lazzari C, Graziano P, et al
    Prospective Validation of the Italian Alliance Against Cancer Lung Panel in Patients With Advanced Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2021 Feb 25. pii: S1525-7304(20)30350.
    PubMed     Abstract available


  216. KIKUCHI Y, Nakatani Y, Yamaguchi T
    Where Is the Primary Site of the Extra-Axial Chordoma Masquerading As Lung Cancer?
    Clin Lung Cancer. 2021 Feb 24. pii: S1525-7304(21)00047.
    PubMed    


  217. BALL S, Dash A, Igid HP, Thein KZ, et al
    Extra-axial Chordoma Masquerading as Lung Cancer.
    Clin Lung Cancer. 2021 Feb 23. pii: S1525-7304(21)00048.
    PubMed    


  218. ARGIRIS A, Miao J, Cristea MC, Chen AM, et al
    A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811).
    Clin Lung Cancer. 2021 Feb 19. pii: S1525-7304(21)00032.
    PubMed     Abstract available


  219. GARON EB, Cho BC, Reinmuth N, Lee KH, et al
    Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC).
    Clin Lung Cancer. 2021 Feb 19. pii: S1525-7304(21)00033.
    PubMed     Abstract available


  220. KOGURE Y, Hashimoto H, Oki M
    A Randomized Phase III Study of Pembrolizumab Versus Pembrolizumab-Carboplatin-Pemetrexed for Locally Advanced or Metastatic Nonsquamous Non-small-cell Lung Cancer with PD-L1 50% or more (LAPLACE-50): Study Protocol.
    Clin Lung Cancer. 2021 Feb 19. pii: S1525-7304(21)00031.
    PubMed     Abstract available


  221. PENG L, Deng HY, Yang Y
    Lobe-specific Lymph Node Dissection for Clinical Stage IA Non-small-cell Lung Cancer: What do we know?
    Clin Lung Cancer. 2021 Feb 16. pii: S1525-7304(21)00030.
    PubMed    


  222. BOYCE-FAPPIANO D, Nguyen QN, Chapman BV, Allen PK, et al
    Single Institution Experience of Proton and Photon-based Postoperative Radiation Therapy for Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2021 Feb 7. pii: S1525-7304(21)00025.
    PubMed     Abstract available


  223. LIN X, Jiao H, Pang Z, Chen H, et al
    Lung Cancer and Granuloma Identification Using a Deep Learning Model to Extract 3-Dimensional Radiomics Features in CT Imaging.
    Clin Lung Cancer. 2021 Feb 6. pii: S1525-7304(21)00027.
    PubMed     Abstract available


  224. FERRARA MG, Martini M, D'Argento E, Forcella C, et al
    PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors.
    Clin Lung Cancer. 2021 Feb 5. pii: S1525-7304(20)30351.
    PubMed     Abstract available


  225. GOULART BHL, Chennupati S, Fedorenko CR, Ramsey SD, et al
    Access to Tyrosine Kinase Inhibitors and Survival in Patients with Advanced EGFR(+) and ALK(+) Positive Non-small-cell Lung Cancer Treated in the Real-World.
    Clin Lung Cancer. 2021 Feb 4. pii: S1525-7304(21)00022.
    PubMed     Abstract available


  226. SHINTANI T, Kishi N, Matsuo Y, Ogura M, et al
    Incidence and Risk Factors of Symptomatic Radiation Pneumonitis in Non-Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy and Consolidation Durvalumab.
    Clin Lung Cancer. 2021 Feb 4. pii: S1525-7304(21)00020.
    PubMed     Abstract available


  227. LI GJ, Tan H, Chen H, Parmar A, et al
    Immunotherapy and Stereotactic Ablative Radiotherapy for Lung Cancer with Co-existing Interstitial Lung Disease: A Case Report.
    Clin Lung Cancer. 2021 Feb 4. pii: S1525-7304(21)00021.
    PubMed    


  228. KIRKLAND RS, Kole AJ, Batra H, Boggs DH, et al
    Predictors of In-Hospital Death in Patients with Lung Cancer Admitted for Acute Radiation Pneumonitis: A Healthcare Cost and Utilization Project (HCUP) Analysis.
    Clin Lung Cancer. 2021 Feb 3. pii: S1525-7304(21)00019.
    PubMed     Abstract available


    January 2021
  229. KERRIGAN K, Wang X, Haaland B, Adamson B, et al
    Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers by Actionable Mutation Status.
    Clin Lung Cancer. 2021 Jan 26. pii: S1525-7304(21)00016.
    PubMed     Abstract available


  230. MATTES MD, Eubank TD, Almubarak M, Wen S, et al
    A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Jan 25. pii: S1525-7304(21)00015.
    PubMed     Abstract available


  231. SHUKLA NA, Althouse S, Meyer Z, Hanna N, et al
    Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2021 Jan 23. pii: S1525-7304(21)00002.
    PubMed     Abstract available


  232. MERRITT RE, Abdel-Rasoul M, D'Souza DM, Kneuertz PJ, et al
    Racial Disparities in Overall Survival and Surgical Treatment for Early Stage Lung Cancer by Facility Type.
    Clin Lung Cancer. 2021 Jan 22. pii: S1525-7304(21)00010.
    PubMed     Abstract available


  233. KEISER MF, Patel AB, Altan M
    Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy.
    Clin Lung Cancer. 2021 Jan 22. pii: S1525-7304(21)00009.
    PubMed     Abstract available


  234. LIU J, Hui C, Ladbury C, Waddington T, et al
    Improved Survival Outcomes in Medically Fit Patients With Early-Stage Non-Small-Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy.
    Clin Lung Cancer. 2021 Jan 19. pii: S1525-7304(21)00006.
    PubMed     Abstract available


  235. OWONIKOKO TK, Redman MW, Byers LA, Hirsch FR, et al
    Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G.
    Clin Lung Cancer. 2021 Jan 10. pii: S1525-7304(21)00004.
    PubMed     Abstract available


  236. CHAN SWS, Smith E, Aggarwal R, Balaratnam K, et al
    Systemic Inflammatory Markers of Survival in Epidermal Growth Factor-Mutated Non-Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis.
    Clin Lung Cancer. 2021 Jan 10. pii: S1525-7304(21)00005.
    PubMed     Abstract available


  237. LU S, Casarini I, Kato T, Cobo M, et al
    Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress.
    Clin Lung Cancer. 2021 Jan 6. pii: S1525-7304(20)30337.
    PubMed     Abstract available


  238. AL-AHMADI A, Ardeshir-Larijani F, Fu P, Cao S, et al
    Next Generation Sequencing of Advanced Non-Small Cell Lung Cancer: Utilization Based on Race and Impact on Survival.
    Clin Lung Cancer. 2021;22:16-22.
    PubMed     Abstract available


  239. RIESS JW, Frankel P, Shackelford D, Dunphy M, et al
    Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design.
    Clin Lung Cancer. 2021;22:67-70.
    PubMed     Abstract available


  240. URBAN L, Doczi R, Vodicska B, Tihanyi D, et al
    Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation.
    Clin Lung Cancer. 2021;22:e112-e115.
    PubMed    


  241. STEBER CR, Hughes RT, Soike MH, Jacobson T, et al
    Five- Versus Ten-Fraction Regimens of Stereotactic Body Radiation Therapy for Primary and Metastatic NSCLC.
    Clin Lung Cancer. 2021;22:e122-e131.
    PubMed     Abstract available


  242. NAGASAKA M, Fisher A, Chowdhury T, Ge Y, et al
    PLEKHH2-ALK: A Novel In-frame Fusion With Durable Response to Alectinib: Utilizing RNA Sequencing in Search for Hidden Gene Fusions Susceptible to Targeted Therapy.
    Clin Lung Cancer. 2021;22:e51-e53.
    PubMed    


  243. EMEREL L, Trejo Bittar H, Okusanya OT
    A Rare Presentation of Primary Pulmonary Synovial Sarcoma.
    Clin Lung Cancer. 2021;22:e48-e50.
    PubMed    


  244. CHEN K, Zhang F, Pan G, Sheng J, et al
    A Case of Resistance to Selective RET-TKI Therapy With Pleural-Genotyped MET Amplification and Response to Crizotinib.
    Clin Lung Cancer. 2021;22:e1-e4.
    PubMed    


    December 2020
  245. KAMIGAICHI A, Tsutani Y, Mimae T, Miyata Y, et al
    Prediction of Unexpected N2 Disease Associated With Clinical T1-2N0-1M0 Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2020 Dec 27. pii: S1525-7304(20)30364.
    PubMed     Abstract available


  246. YAMAMOTO N, Harada H, Okamoto I, Masuda N, et al
    Phase 2 Study of Nimotuzumab in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2020 Dec 26. pii: S1525-7304(20)30366.
    PubMed     Abstract available


  247. MALLER B, Simmons VN, Byrne MM, Tanvetyanon T, et al
    Characteristics and Outcomes of Lung Cancer Screening Among Individuals With or Without Cancer History.
    Clin Lung Cancer. 2020 Dec 19. pii: S1525-7304(20)30349.
    PubMed     Abstract available


  248. WANG X, Jiang S, You X, Aramini B, et al
    Extended Sleeve Lobectomy is an Alternative for Centrally Located Lung Cancer With Superior Short- and Long-term Outcomes.
    Clin Lung Cancer. 2020 Dec 17. pii: S1525-7304(20)30345.
    PubMed     Abstract available


  249. RAZ DJ, Ismail MH, Haupt EC, Sun V, et al
    Improving Utilization of Lung Cancer Screening Through Incorporating a Video-Based Educational Tool Into Smoking Cessation Counseling.
    Clin Lung Cancer. 2020 Dec 15. pii: S1525-7304(20)30346.
    PubMed     Abstract available


  250. GERBER DE, Hamann HA, Dorsey O, Ahn C, et al
    Clinician Variation in Ordering and Completion of Low-Dose Computed Tomography for Lung Cancer Screening in a Safety-Net Medical System.
    Clin Lung Cancer. 2020 Dec 11. pii: S1525-7304(20)30344.
    PubMed     Abstract available


  251. BUSTAMANTE ALVAREZ JG, Janse S, Owen DH, Kiourtsis S, et al
    Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
    Clin Lung Cancer. 2020 Dec 2. pii: S1525-7304(20)30340.
    PubMed     Abstract available


  252. HYSELL K, Yusuf R, Barakat L, Virata M, et al
    Decreased Overall Survival in HIV-associated Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2020 Dec 2. pii: S1525-7304(20)30339.
    PubMed     Abstract available


  253. METZENMACHER M, Goetz M, Herold T, Stuschke M, et al
    Acquired Resistance to BRAF/MEK Inhibitor Therapy in BRAF-V(600)-mutated Squamous Cell Lung Cancer: Concurrent Evolvement of PTEN and MEK1 Mutations.
    Clin Lung Cancer. 2020 Dec 2. pii: S1525-7304(20)30341.
    PubMed    


    November 2020
  254. LI T, Pan K, Ellinwood AK, Cress RD, et al
    Survival Trends of Metastatic Lung Cancer in California by Age at Diagnosis, Gender, Race/Ethnicity, and Histology, 1990-2014.
    Clin Lung Cancer. 2020 Nov 24. pii: S1525-7304(20)30338.
    PubMed     Abstract available


  255. YIN W, Cheng J, Tang Z, Toruner G, et al
    MET Amplification (MET/CEP7 Ratio >/= 1.8) Is an Independent Poor Prognostic Marker in Patients With Treatment-naive Non-Small-cell Lung Cancer.
    Clin Lung Cancer. 2020 Nov 17. pii: S1525-7304(20)30335.
    PubMed     Abstract available


  256. HANDA Y, Tsutani Y, Mimae T, Miyata Y, et al
    Surgical Procedure Selection for Stage I Lung Cancer: Complex Segmentectomy versus Wedge Resection.
    Clin Lung Cancer. 2020 Nov 17. pii: S1525-7304(20)30331.
    PubMed     Abstract available


  257. LI XM, Li WF, Lin JT, Yan HH, et al
    Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901).
    Clin Lung Cancer. 2020 Nov 17. pii: S1525-7304(20)30334.
    PubMed     Abstract available


  258. BALASUBRAMANIAN A, Onggo J, Gunjur A, John T, et al
    Immune Checkpoint Inhibition With Chemoradiotherapy in Stage III Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis of Safety Results.
    Clin Lung Cancer. 2020 Nov 12. pii: S1525-7304(20)30333.
    PubMed     Abstract available


  259. SUN L, Davis CW, Hwang WT, Jeffries S, et al
    Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy.
    Clin Lung Cancer. 2020 Nov 11. pii: S1525-7304(20)30327.
    PubMed     Abstract available


  260. ENRIGHT TL, Witt JS, Burr AR, Yadav P, et al
    Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non-small-cell Lung Cancer Brain Metastases.
    Clin Lung Cancer. 2020 Nov 10. pii: S1525-7304(20)30324.
    PubMed     Abstract available


  261. BORGHAEI H, Redman MW, Kelly K, Waqar SN, et al
    SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study).
    Clin Lung Cancer. 2020 Nov 10. pii: S1525-7304(20)30325.
    PubMed     Abstract available


  262. NIE Y, Wang X, Yang F, Zhou Z, et al
    Surgical Prognosis of Synchronous Multiple Primary Lung Cancer: Systematic Review and Meta-Analysis.
    Clin Lung Cancer. 2020 Nov 5. pii: S1525-7304(20)30332.
    PubMed     Abstract available


  263. OWEN DH, Benner B, Pilcher C, Good L, et al
    Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells.
    Clin Lung Cancer. 2020 Nov 2. pii: S1525-7304(20)30328.
    PubMed    


    October 2020
  264. HARATAKE N, Seto T
    NTRK Fusion-positive Non-small-cell Lung Cancer: The Diagnosis and Targeted Therapy.
    Clin Lung Cancer. 2020 Oct 24. pii: S1525-7304(20)30315.
    PubMed     Abstract available


  265. MERRITT RE, Abdel-Rasoul M, Fitzgerald M, D'Souza DM, et al
    Nomograms for Predicting Overall and Recurrence-free Survival From Pathologic Stage IA and IB Lung Cancer After Lobectomy.
    Clin Lung Cancer. 2020 Oct 22. pii: S1525-7304(20)30311.
    PubMed     Abstract available


  266. GARRANA SH, Dagogo-Jack I, Cobb R, Kuo AH, et al
    Clinical and Imaging Features of Non-Small-Cell Lung Cancer in Young Patients.
    Clin Lung Cancer. 2020 Oct 21. pii: S1525-7304(20)30314.
    PubMed     Abstract available


  267. MA J, Pi G, Bi J, Li Y, et al
    Concurrent Apatinib and Brain Radiotherapy in Patients With Brain Metastases From Driver Mutation-negative Non-small-cell Lung Cancer: Study Protocol for an Open-label Randomized Controlled Trial.
    Clin Lung Cancer. 2020 Oct 21. pii: S1525-7304(20)30309.
    PubMed     Abstract available


  268. RIUDAVETS M, Caramella C, Pradere P, Naltet C, et al
    Complete, Unpredictable, Multi-site Response Including Brain and Liver Metastases in a Patient With RET-rearranged Non-small-cell Lung Cancer Treated With Single-agent Immunotherapy: A Case Report.
    Clin Lung Cancer. 2020 Oct 21. pii: S1525-7304(20)30313.
    PubMed    


  269. MELE MC, Rinninella E, Cintoni M, Pulcini G, et al
    Nutritional Support in Lung Cancer Patients: The State of the Art.
    Clin Lung Cancer. 2020 Oct 21. pii: S1525-7304(20)30310.
    PubMed     Abstract available


  270. ASAHINA H, Tanaka K, Morita S, Maemondo M, et al
    A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801).
    Clin Lung Cancer. 2020 Oct 16. pii: S1525-7304(20)30305.
    PubMed     Abstract available


  271. FRIIS RB, Hjollund NH, Pappot H, Taarnhoj GA, et al
    Patient-Reported Outcome Measures Used in Routine Care Predict for Survival at Disease Progression in Patients With Advanced Lung Cancer.
    Clin Lung Cancer. 2020 Oct 15. pii: S1525-7304(20)30294.
    PubMed     Abstract available


  272. SHAH AT, Bernardo RJ, Berry GJ, Kudelko K, et al
    Two Cases of Pulmonary Tumor Thrombotic Microangiopathy Associated with ROS1-Rearranged Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2020 Oct 15. pii: S1525-7304(20)30302.
    PubMed    


  273. YU H, Brustugun OT, Ekman S, Botling J, et al
    Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2020 Oct 15. pii: S1525-7304(20)30299.
    PubMed     Abstract available


  274. ZHAO Y, Mao Y, He J, Gao S, et al
    Lobe-specific Lymph Node Dissection in Clinical Stage IA Solid-dominant Non-small-cell Lung Cancer: A Propensity Score Matching Study.
    Clin Lung Cancer. 2020 Oct 15. pii: S1525-7304(20)30291.
    PubMed     Abstract available


  275. TANAKA H, Hasegawa Y, Makiguchi T, Okumura F, et al
    A Phase I/II Study of Biweekly Carboplatin and Nab-paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced Unresectable Stage III Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2020 Oct 14. pii: S1525-7304(20)30296.
    PubMed     Abstract available


  276. ZHANG J, Liu L, Wang G, Li S, et al
    Skip N2 Metastasis Shows Similar Prognosis to N1 Disease in Lung Cancer: Mechanism Discussion.
    Clin Lung Cancer. 2020 Oct 14. pii: S1525-7304(20)30306.
    PubMed    


  277. HE Z, Li Z, Xu S, Wu W, et al
    Prognostic Significance of Lymph Node Count Removed at Sublobar Resection in Pathologic Stage IA Non-Small-cell Lung Cancer: A Population-Based Analysis.
    Clin Lung Cancer. 2020 Oct 14. pii: S1525-7304(20)30295.
    PubMed     Abstract available


  278. JANSEN AME, Sriram JD, Pluim D, Maas RJH, et al
    Therapeutic Exposure and Successful Response to Pembrolizumab in a Patient With Non-Small-Cell Lung Cancer Despite Significant Renal Loss Due to Paraneoplastic Nephrotic Syndrome.
    Clin Lung Cancer. 2020 Oct 14. pii: S1525-7304(20)30303.
    PubMed    


  279. WAQAR SN, Redman MW, Arnold SM, Hirsch FR, et al
    A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).
    Clin Lung Cancer. 2020 Oct 14. pii: S1525-7304(20)30293.
    PubMed     Abstract available


  280. PARK M, Ho DY, Wakelee HA, Neal JW, et al
    Opportunistic Invasive Fungal Infections Mimicking Progression of Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2020 Oct 13. pii: S1525-7304(20)30292.
    PubMed     Abstract available


    September 2020
  281. ZHU YJ, Qu X, Zhan DD, Chen HH, et al
    Specific Gene Co-variation Acts Better Than Number of Concomitant Altered Genes in Predicting EGFR-TKI Efficacy in Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2020 Sep 19. pii: S1525-7304(20)30264.
    PubMed     Abstract available


  282. CITARELLA F, Russano M, Galletti A, Vincenzi B, et al
    Multiple and Concomitant Molecular Findings in a Heavily Treated Patient With EGFR-positive Lung Cancer.
    Clin Lung Cancer. 2020 Sep 18. pii: S1525-7304(20)30262.
    PubMed    


  283. CUSHMAN TR, Jones B, Akhavan D, Rusthoven CG, et al
    The Effects of Time to Treatment Initiation for Patients With Non-small-cell Lung Cancer in the United States.
    Clin Lung Cancer. 2020 Sep 18. pii: S1525-7304(20)30265.
    PubMed     Abstract available


  284. DENG Z, Qin Y, Liu Y, Zhang Y, et al
    Role of Antiangiogenic Agents Combined With EGFR Tyrosine Kinase Inhibitors in Treatment-naive Lung Cancer: A Meta-Analysis.
    Clin Lung Cancer. 2020 Sep 18. pii: S1525-7304(20)30271.
    PubMed     Abstract available


  285. VAN DE WIEL M, Derijcke S, Galdermans D, Daenen M, et al
    Coping Strategy Influences Quality of Life in Patients With Advanced Lung Cancer by Mediating Mood.
    Clin Lung Cancer. 2020 Sep 18. pii: S1525-7304(20)30274.
    PubMed     Abstract available


  286. SPIGEL DR, Jotte RM, Aix SP, Gressot L, et al
    Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.
    Clin Lung Cancer. 2020 Sep 18. pii: S1525-7304(20)30270.
    PubMed     Abstract available


  287. EKEKE CN, Mitchell C, Schuchert M, Dhupar R, et al
    Early Distant Recurrence in Patients With Resected Stage I Lung Cancer: A Case Series of "Blast Metastasis".
    Clin Lung Cancer. 2020 Sep 18. pii: S1525-7304(20)30263.
    PubMed     Abstract available


  288. GOWER A, Kim J, Spector K, Menashe D, et al
    Three Primary Tumors Including EGFR-mutated Non-Small Cell Lung Cancer as First Presentation in Patient With Li-Fraumeni Syndrome.
    Clin Lung Cancer. 2020 Sep 18. pii: S1525-7304(20)30267.
    PubMed    


  289. BOWMAN L, Tiu R, Smyth EN, Willard MD, et al
    Clinical Characteristics, Treatments, and Concurrent Mutations in Non-Small Cell Lung Cancer Patients With NF1 Mutations.
    Clin Lung Cancer. 2020 Sep 18. pii: S1525-7304(20)30275.
    PubMed     Abstract available


  290. JAHANZEB M, Lin HM, Pan X, Yin Y, et al
    Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2020 Sep 18. pii: S1525-7304(20)30268.
    PubMed     Abstract available


  291. PASSARO A, Spitaleri G, de Marinis F
    Reply.
    Clin Lung Cancer. 2020;21:e415-e416.
    PubMed    


  292. CALIMAN E, Petreni P, Brugia M, Antonuzzo L, et al
    In Regard to "Activity of EGFR TKIs in Caucasian Patients With NSCLC Harbouring Potentially Sensitive Uncommon EGFR Mutations".
    Clin Lung Cancer. 2020;21:e363-e365.
    PubMed    


    August 2020
  293. BONOMI M, Maltese M, Brighenti M, Muri M, et al
    Tocilizumab for COVID-19 Pneumonia in a Patient With Non-Small-cell Lung Cancer Treated With Chemoimmunotherapy.
    Clin Lung Cancer. 2020 Aug 26. pii: S1525-7304(20)30254.
    PubMed    


  294. GOROSPE L, Ayala-Carbonero AM, Paredes-Rodriguez P, Munoz-Molina GM, et al
    Challenges in Management of Patients With Lung Cancer in Times of COVID-19: An Imaging Perspective.
    Clin Lung Cancer. 2020 Aug 25. pii: S1525-7304(20)30253.
    PubMed    


  295. SOOD S, Ganju R, Shen X, Napel MT, et al
    Ultra-central Thoracic Re-irradiation Using 10-fraction Stereotactic Body Radiotherapy for Recurrent Non-small-cell Lung Cancer Tumors: Preliminary Toxicity and Efficacy Outcomes.
    Clin Lung Cancer. 2020 Aug 11. pii: S1525-7304(20)30150.
    PubMed     Abstract available


  296. OH MS, Guzner A, Wainwright DA, Mohindra NA, et al
    The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
    Clin Lung Cancer. 2020 Aug 5. pii: S1525-7304(20)30238.
    PubMed     Abstract available


  297. CHIC N, Mezquita L, Aldea M, Chebib R, et al
    Successful Switch to Vemurafenib Plus Cobimetinib After Dabrafenib Plus Trametinib Toxicity in BRAF(V600E)-Mutant Metastatic Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2020 Aug 5. pii: S1525-7304(20)30235.
    PubMed    


  298. PASSIGLIA F, Bironzo P, Righi L, Listi A, et al
    A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes:
    Clin Lung Cancer. 2020 Aug 5. pii: S1525-7304(20)30236.
    PubMed     Abstract available


    July 2020
  299. CHEN XR, Hou X, Li DL, Sai K, et al
    Management of Non-Small-Cell Lung Cancer Patients Initially Diagnosed With 1 to 3 Synchronous Brain-Only Metastases: A Retrospective Study.
    Clin Lung Cancer. 2020 Jul 30. pii: S1525-7304(20)30233.
    PubMed     Abstract available


  300. DARWIN A, Rose T, Tandon A, Tanvetyanon T, et al
    Development of Bronchopleural Fistula After Durvalumab Consolidation for Stage III Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2020 Jul 30. pii: S1525-7304(20)30232.
    PubMed    


  301. MANKUZHY NP, Almahariq MF, Siddiqui ZA, Thompson AB, et al
    The Role of Postoperative Radiation Therapy for pN2 Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2020 Jul 30. pii: S1525-7304(20)30230.
    PubMed     Abstract available


  302. HALL PE, Ready N, Johnston A, Bomalaski JS, et al
    Phase II Study of Arginine Deprivation Therapy With Pegargiminase in Patients With Relapsed Sensitive or Refractory Small-cell Lung Cancer.
    Clin Lung Cancer. 2020 Jul 30. pii: S1525-7304(20)30234.
    PubMed     Abstract available


  303. STENEHJEM DD, Lubinga SJ, Gupte-Singh K, Zhang Y, et al
    Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Non-Small-Cell Lung Cancer in the United States.
    Clin Lung Cancer. 2020 Jul 29. pii: S1525-7304(20)30231.
    PubMed     Abstract available


  304. ZHENG J, Shen L, Jiang N, Zhu Y, et al
    First-in-Human Phase 1 Study of ES-072, an Oral Mutant-Selective EGFR T790M Inhibitor, in Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2020 Jul 9. pii: S1525-7304(20)30223.
    PubMed     Abstract available


  305. CHANG Q, Xu J, Qiang H, Teng J, et al
    EGFR Tyrosine Kinase Inhibitor (TKI) Combined With Concurrent or Sequential Chemotherapy for Patients With Advanced Lung Cancer and Gradual Progression After First-Line EGFR-TKI Therapy: A Randomized Controlled Study.
    Clin Lung Cancer. 2020 Jul 6. pii: S1525-7304(20)30187.
    PubMed     Abstract available


  306. BLAKELY AM, Hu H, Wong FL, Raz DJ, et al
    Deterioration in Health-Related Quality of Life Diminishes Benefit of Lung Cancer Resection in Older Adults.
    Clin Lung Cancer. 2020 Jul 3. pii: S1525-7304(20)30216.
    PubMed     Abstract available


  307. SHEIKHBAHAEI S, Verde F, Hales RK, Rowe SP, et al
    Imaging in Therapy Response Assessment and Surveillance of Lung Cancer: Evidenced-based Review With Focus on the Utility of (18)F-FDG PET/CT.
    Clin Lung Cancer. 2020 Jul 3. pii: S1525-7304(20)30214.
    PubMed     Abstract available


  308. MERRITT RE, Kneuertz PJ
    Considerations for the Surgical Management of Early Stage Lung Cancer During the COVID-19 Pandemic.
    Clin Lung Cancer. 2020 Jul 3. pii: S1525-7304(20)30218.
    PubMed     Abstract available


  309. BOURHIS A, Remoue A, Uguen A
    KRAS and BRAF Double Mutations and Functional Classes of BRAF Mutations in Non-small-cell Lung Cancers.
    Clin Lung Cancer. 2020;21:e240-e242.
    PubMed    


    June 2020
  310. WONG W, Wu N, Gupta R, Mansfield AS, et al
    Utilization Trends and Factors Associated With ROS1 Testing Among Patients With Advanced Non-small-cell Lung Cancer in US Community Practices.
    Clin Lung Cancer. 2020 Jun 29. pii: S1525-7304(20)30213.
    PubMed     Abstract available


  311. MIERAS A, Pasman HRW, Klop HT, Onwuteaka-Philipsen BD, et al
    What Goals Do Patients and Oncologists Have When Starting Medical Treatment for Metastatic Lung Cancer?
    Clin Lung Cancer. 2020 Jun 21. pii: S1525-7304(20)30208.
    PubMed     Abstract available


  312. RECKAMP KL, Patil T, Kirtane K, Rich TA, et al
    Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis.
    Clin Lung Cancer. 2020 Jun 20. pii: S1525-7304(20)30209.
    PubMed     Abstract available


  313. AUGUSTYN A, Adams DL, He J, Qiao Y, et al
    Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Non-Small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab.
    Clin Lung Cancer. 2020 Jun 20. pii: S1525-7304(20)30210.
    PubMed     Abstract available


  314. ZHAO Y, Zhai L, Deng L, Halmos B, et al
    Efficacy of Osimertinib in Afatinib-resistant Lung Cancer Harboring Uncommon EGFR Mutations: Case Report and Literature Review.
    Clin Lung Cancer. 2020 Jun 19. pii: S1525-7304(20)30211.
    PubMed    


  315. MULLER DA, Dutta SW, Aliotta E, Sanders JC, et al
    Clinical Outcomes and Predictors of Lung Toxicity After Multiple Courses of Lung Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2020 Jun 12. pii: S1525-7304(20)30188.
    PubMed     Abstract available


  316. PATEL JD, Lee JW, Carbone DP, Wagner H, et al
    Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).
    Clin Lung Cancer. 2020 Jun 12. pii: S1525-7304(20)30189.
    PubMed     Abstract available


  317. COSTA GJ, Silva GTD, Ferreira CG, Mello MJG, et al
    Brazilian Women With Lung Cancer Have a Higher Overall Survival Than Their Male Equivalents: A Cohort Study.
    Clin Lung Cancer. 2020 Jun 6. pii: S1525-7304(20)30162.
    PubMed     Abstract available


  318. SEHGAL K, Bulumulle A, Brody H, Gill RR, et al
    Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2020 Jun 5. pii: S1525-7304(20)30168.
    PubMed     Abstract available


  319. TSIMBERIDOU AM, Elkin S, Dumanois R, Pritchard D, et al
    Clinical and Economic Value of Genetic Sequencing for Personalized Therapy in Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2020 Jun 5. pii: S1525-7304(20)30169.
    PubMed     Abstract available


  320. URBANSKA EM, Santoni-Rugiu E, Melchior LC, Carlsen JF, et al
    Intracranial Response of ALK(+) Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic Radiosurgery.
    Clin Lung Cancer. 2020 Jun 4. pii: S1525-7304(20)30135.
    PubMed    


  321. GUERINI AE, Borghetti P, Filippi AR, Bonu ML, et al
    Differential Diagnosis and Clinical Management of a Case of COVID-19 in a Patient With Stage III Lung Cancer Treated With Radio-chemotherapy and Durvalumab.
    Clin Lung Cancer. 2020 Jun 2. pii: S1525-7304(20)30167.
    PubMed    


  322. SITTENFELD SMC, Juloori A, Reddy CA, Stephans KL, et al
    Salvage Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Primary Surgical Resection of Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2020 Jun 2. pii: S1525-7304(20)30165.
    PubMed     Abstract available


  323. UPRETY D, Borgert AJ, Fitzsimmons AJ, Parsons BM, et al
    External Validation of AJCC Eighth Edition of Non-small-cell Lung Cancer Staging Among African Americans.
    Clin Lung Cancer. 2020 Jun 2. pii: S1525-7304(20)30170.
    PubMed     Abstract available


  324. ELBANNA M, Shiue K, Edwards D, Cerra-Franco A, et al
    Impact of Lung Parenchymal-Only Failure on Overall Survival in Early-Stage Lung Cancer Patients Treated With Stereotactic Ablative Radiotherapy.
    Clin Lung Cancer. 2020 Jun 2. pii: S1525-7304(20)30164.
    PubMed     Abstract available


    May 2020
  325. BYLICKI O, Riviere F, Tournier C, Canoui-Poitrine F, et al
    Factors Associated With Aggressiveness of End-of-Life Care for Lung Cancer Patients and Associated Costs of Care.
    Clin Lung Cancer. 2020 May 23. pii: S1525-7304(20)30157.
    PubMed     Abstract available


  326. HIRSCH EA, New ML, Brown SL, Baron AE, et al
    Impact of a Hybrid Lung Cancer Screening Model on Patient Outcomes and Provider Behavior.
    Clin Lung Cancer. 2020 May 23. pii: S1525-7304(20)30158.
    PubMed     Abstract available


  327. FRIEDES C, Mai N, Hazell S, Fu W, et al
    Consolidative Radiotherapy in Oligometastatic Lung Cancer: Patient Selection With a Prediction Nomogram.
    Clin Lung Cancer. 2020 May 23. pii: S1525-7304(20)30153.
    PubMed     Abstract available


  328. GIJTENBEEK RGP, Damhuis RAM, Groen HJM, van der Wekken AJ, et al
    Nationwide Real-world Cohort Study of First-line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2020 May 22. pii: S1525-7304(20)30159.
    PubMed     Abstract available


  329. MIURA S, Yamanaka T, Kato T, Ikeda S, et al
    Treatment Rationale and Design of a Phase III Study of Afatinib or Chemotherapy in Patients with Non-small-cell Lung Cancer Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations (ACHILLES/TORG1834).
    Clin Lung Cancer. 2020 May 21. pii: S1525-7304(20)30151.
    PubMed     Abstract available


  330. ENDOH H, Yamamoto R, Ichikawa A, Shiozawa S, et al
    Clinicopathologic Significance of False-Positive Lymph Node Status on FDG-PET in Lung Cancer.
    Clin Lung Cancer. 2020 May 14. pii: S1525-7304(20)30142.
    PubMed     Abstract available


  331. LUCIANI A, Marra A, Toschi L, Cortinovis D, et al
    Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged >/= 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study.
    Clin Lung Cancer. 2020 May 13. pii: S1525-7304(20)30144.
    PubMed     Abstract available


  332. CHIANG AC, Sequist LVD, Gilbert J, Conkling P, et al
    Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer.
    Clin Lung Cancer. 2020 May 12. pii: S1525-7304(20)30148.
    PubMed     Abstract available


  333. BALL S, Dash A, Igid HP, Thein KZ, et al
    Primary Extra-axial Chordoma Masquerading as Lung Cancer: Case Report and Review of the Literature.
    Clin Lung Cancer. 2020 May 11. pii: S1525-7304(20)30141.
    PubMed    


  334. GOBBINI E, Toffart AC, Perol M, Assie JB, et al
    Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients.
    Clin Lung Cancer. 2020 May 8. pii: S1525-7304(20)30136.
    PubMed     Abstract available


  335. KAMIGAICHI A, Tsutani Y, Kagimoto A, Fujiwara M, et al
    Comparing Segmentectomy and Lobectomy for Clinical Stage IA Solid-dominant Lung Cancer Measuring 2.1 to 3 cm.
    Clin Lung Cancer. 2020 May 7. pii: S1525-7304(20)30138.
    PubMed     Abstract available


  336. IJSSELDIJK MA, Shoni M, Siegert C, Wiering B, et al
    Oncologic Outcomes of Surgery Versus SBRT for Non-Small-Cell Lung Carcinoma: A Systematic Review and Meta-analysis.
    Clin Lung Cancer. 2020 May 7. pii: S1525-7304(20)30140.
    PubMed     Abstract available


    April 2020
  337. FRIEDLAENDER A, Liu SV, Passaro A, Metro G, et al
    The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors.
    Clin Lung Cancer. 2020 Apr 30. pii: S1525-7304(20)30105.
    PubMed     Abstract available


  338. MORAN T, Taus A, Arriola E, Aguado C, et al
    Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study.
    Clin Lung Cancer. 2020 Apr 25. pii: S1525-7304(20)30134.
    PubMed     Abstract available


  339. STINCHCOMBE TE, Miksad RA, Gossai A, Griffith SD, et al
    Real-World Outcomes for Advanced Non-Small Cell Lung Cancer Patients Treated With a PD-L1 Inhibitor Beyond Progression.
    Clin Lung Cancer. 2020 Apr 18. pii: S1525-7304(20)30107.
    PubMed     Abstract available


  340. DE GIGLIO A, Lamberti G, Facchinetti F, Genova C, et al
    Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib.
    Clin Lung Cancer. 2020 Apr 15. pii: S1525-7304(20)30087.
    PubMed     Abstract available


  341. SHEN E, Xiu J, Bentley R, Lopez GY, et al
    Frequent Mutations of POT1 Distinguish Pulmonary Sarcomatoid Carcinoma From Other Lung Cancer Histologies.
    Clin Lung Cancer. 2020 Apr 15. pii: S1525-7304(20)30101.
    PubMed     Abstract available


  342. GELATTI ACZ, Cordeiro de Lima VC, Freitas H, Werutsky G, et al
    Real-World Prevalence of PD-L1 Expression Among Tumor Samples From Patients With Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2020 Apr 13. pii: S1525-7304(20)30106.
    PubMed     Abstract available


  343. ABDEL-RAHMAN O
    Incidence and Mortality of Lung Cancer Among Never Smokers in Relationship to Secondhand Smoking: Findings From the PLCO Trial.
    Clin Lung Cancer. 2020 Apr 13. pii: S1525-7304(20)30108.
    PubMed     Abstract available


  344. CATHCART-RAKE EJ, Sangaralingham LR, Henk HJ, Shah ND, et al
    A Population-based Study of Immunotherapy-related Toxicities in Lung Cancer.
    Clin Lung Cancer. 2020 Apr 13. pii: S1525-7304(20)30102.
    PubMed     Abstract available


  345. KIM J, Hyun HJ, Choi EA, Yoo JW, et al
    Diabetes, Metformin, and Lung Cancer: Retrospective Study of the Korean NHIS-HEALS Database.
    Clin Lung Cancer. 2020 Apr 13. pii: S1525-7304(20)30100.
    PubMed     Abstract available


  346. MUKTHINUTHALAPATI VVPK, Putta A, Farooq MZ, Singh SRK, et al
    Knowledge, Attitudes, and Practices Pertaining to Lung Cancer Screening Among Primary Care Physicians in a Public Urban Health Network.
    Clin Lung Cancer. 2020 Apr 11. pii: S1525-7304(20)30083.
    PubMed     Abstract available


  347. SHIRAISHI Y, Kishimoto J, Tanaka K, Sugawara S, et al
    Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2020 Apr 10. pii: S1525-7304(20)30089.
    PubMed     Abstract available


  348. MAYNE NR, Mallipeddi MK, Darling AJ, Jeffrey Yang CF, et al
    Impact of Surveillance After Lobectomy for Lung Cancer on Disease Detection and Survival.
    Clin Lung Cancer. 2020 Apr 10. pii: S1525-7304(20)30099.
    PubMed     Abstract available


    March 2020
  349. CHIAPPETTA M, Leuzzi G, Sperduti I, Bria E, et al
    Mediastinal Up-Staging During Surgery in Non-Small-Cell Lung Cancer: Which Mediastinal Lymph Node Metastasis Patterns Better Predict The Outcome? A Multicenter Analysis.
    Clin Lung Cancer. 2020 Mar 20. pii: S1525-7304(20)30082.
    PubMed     Abstract available


  350. MARTINEZ-MEEHAN D, Lutfi W, Dhupar R, Christie N, et al
    Factors Associated With Survival in Complete Pathologic Response Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2020 Mar 16. pii: S1525-7304(20)30081.
    PubMed     Abstract available


  351. SHUKLA NA, Yan MN, Hanna N
    The Story of Angiogenesis Inhibitors in Non-small-cell Lung Cancer: The Past, Present, and Future.
    Clin Lung Cancer. 2020 Mar 12. pii: S1525-7304(20)30075.
    PubMed     Abstract available


  352. MINARI R, Mazzaschi G, Bordi P, Gnetti L, et al
    Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Rea
    Clin Lung Cancer. 2020 Mar 9. pii: S1525-7304(20)30072.
    PubMed     Abstract available


  353. NAIDOO J, Nishino M, Patel SP, Shankar B, et al
    Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2020 Mar 9. pii: S1525-7304(20)30076.
    PubMed     Abstract available


  354. FARRELL MJ, Yahya JB, Degnin C, Chen Y, et al
    Elective Nodal Irradiation for Limited-stage Small-cell Lung Cancer: Survey of US Radiation Oncologists on Practice Patterns.
    Clin Lung Cancer. 2020 Mar 7. pii: S1525-7304(20)30071.
    PubMed     Abstract available


  355. PRELAJ A, Rebuzzi SE, Pizzutilo P, Bilancia M, et al
    EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non-Small-cell Lung Cancer Treated With Immunotherapy.
    Clin Lung Cancer. 2020 Mar 7. pii: S1525-7304(19)30334.
    PubMed     Abstract available


  356. PRELAJ A, Lo Russo G, Proto C, Signorelli D, et al
    DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation.
    Clin Lung Cancer. 2020 Mar 7. pii: S1525-7304(20)30005.
    PubMed     Abstract available


  357. RAJU S, Khawaja A, Han X, Wang X, et al
    Lung Cancer Screening: Characteristics of Nonparticipants and Potential Screening Barriers.
    Clin Lung Cancer. 2020 Mar 3. pii: S1525-7304(19)30333.
    PubMed     Abstract available


  358. GELSOMINO F, Di Federico A, Filippini DM, Dall'Olio FG, et al
    Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report.
    Clin Lung Cancer. 2020;21:e45-e48.
    PubMed    


  359. BARBOSA MVR, Cordeiro de Lima VC, Formiga MN, Andrade de Paula CA, et al
    High Prevalence of EGFR Mutations in Lung Adenocarcinomas From Brazilian Patients Harboring the TP53 p.R337H Variant.
    Clin Lung Cancer. 2020;21:e37-e44.
    PubMed    


  360. MATSUBARA T, Uchi H, Haratake N, Takamori S, et al
    Acute Generalized Exanthematous Pustulosis Caused by the Combination of Pembrolizumab Plus Chemotherapy in a Patient With Squamous-Cell Carcinoma.
    Clin Lung Cancer. 2020;21:e54-e56.
    PubMed    


  361. MAZZASCHI G, Bordi P, Fioretzaki R, Gnetti L, et al
    Nivolumab-Induced Guillain-Barre Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma.
    Clin Lung Cancer. 2020;21:e65-e73.
    PubMed    


  362. TANNER NT, Brasher PB, Jett J, Silvestri GA, et al
    Effect of a Rule-in Biomarker Test on Pulmonary Nodule Management: A Survey of Pulmonologists and Thoracic Surgeons.
    Clin Lung Cancer. 2020;21:e89-e98.
    PubMed     Abstract available


  363. ZHANG Y, Yu M, Yuan M, Chen R, et al
    Identification of a Novel RBPMS-ROS1 Fusion in an Adolescent Patient With Microsatellite-instable Advanced Lung Adenocarcinoma Sensitive to Crizotinib: A Case Report.
    Clin Lung Cancer. 2020;21:e78-e83.
    PubMed    


  364. KINSLOW CJ, May MS, Saqi A, Shu CA, et al
    Large-Cell Neuroendocrine Carcinoma of the Lung: A Population-Based Study.
    Clin Lung Cancer. 2020;21:e99-e113.
    PubMed     Abstract available


  365. ERSEK JL, Symanowski JT, Han Y, Howard A, et al
    Pulmonary Carcinosarcoma: A Surveillance, Epidemiology, and End Results (SEER) Analysis.
    Clin Lung Cancer. 2020;21:160-170.
    PubMed     Abstract available


    February 2020
  366. MARTIN C, Lupinacci L, Perazzo F, Bas C, et al
    Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina.
    Clin Lung Cancer. 2020 Feb 26. pii: S1525-7304(20)30039.
    PubMed     Abstract available


  367. FINK-NEUBOECK N, Lindenmann J, Porubsky C, Fediuk M, et al
    Hazards of Recurrence, Second Primary, or Other Tumor at Ten Years After Surgery for Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2020 Feb 26. pii: S1525-7304(20)30036.
    PubMed     Abstract available


    January 2020
  368. MARMARELIS ME, Langer CJ
    Treatment of Patients With Non-Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations.
    Clin Lung Cancer. 2020 Jan 27. pii: S1525-7304(20)30010.
    PubMed     Abstract available


  369. MATTAR MS, Chang J, Benayed R, Halpenny D, et al
    Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma.
    Clin Lung Cancer. 2020;21:e25-e29.
    PubMed    


  370. TSUTSUMI H, Yoneshima Y, Ota K, Otsubo K, et al
    Multiclonality and Radiosensitivity of Granulocyte-colony Stimulating Factor-Producing Lung Adenocarcinoma Positive for an Activating EGFR Mutation.
    Clin Lung Cancer. 2020;21:e21-e24.
    PubMed    


  371. FRANCESCHINI D, De Rose F, Cozzi S, Renna I, et al
    Volumetric Modulated Arc Therapy After Lung Sparing Surgery for Malignant Pleural Mesothelioma: A Single Institution Experience.
    Clin Lung Cancer. 2020;21:86-93.
    PubMed     Abstract available


  372. DOI H, Kuribayashi K, Kitajima K, Yamakado K, et al
    Development of a Novel Prognostic Risk Classification System for Malignant Pleural Mesothelioma.
    Clin Lung Cancer. 2020;21:66-74.
    PubMed     Abstract available


  373. GUO HY, Lin JT, Huang HH, Gao Y, et al
    Development and Validation of a (18)F-FDG PET/CT-Based Clinical Prediction Model for Estimating Malignancy in Solid Pulmonary Nodules Based on a Population With High Prevalence of Malignancy.
    Clin Lung Cancer. 2020;21:47-55.
    PubMed     Abstract available


  374. CASTELLO A, Toschi L, Rossi S, Finocchiaro G, et al
    Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy.
    Clin Lung Cancer. 2020;21:28-36.
    PubMed     Abstract available


    November 2019
  375. JELINEK MJ, Armstrong SA, Patel JD, Subramaniam DS, et al
    Identifying Resistance Mechanisms to Osimertinib via Blood Biopsy.
    Clin Lung Cancer. 2019;20:e597-e600.
    PubMed    


  376. GUISIER F, Piton N, Salaun M, Thiberville L, et al
    ROS1-rearranged NSCLC With Secondary Resistance Mutation: Case Report and Current Perspectives.
    Clin Lung Cancer. 2019;20:e593-e596.
    PubMed    


  377. MODING EJ, Liang R, Lartey FM, Maxim PG, et al
    Predictors of Respiratory Decline Following Stereotactic Ablative Radiotherapy to Multiple Lung Tumors.
    Clin Lung Cancer. 2019;20:461-468.
    PubMed     Abstract available


  378. PROTO C, Signorelli D, Mallone S, Prelaj A, et al
    The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma.
    Clin Lung Cancer. 2019;20:e652-e660.
    PubMed     Abstract available


  379. SCHULZ C, Gandara D, Berardo CG, Rosenthal R, et al
    Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies.
    Clin Lung Cancer. 2019;20:451-460.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: